Document:

Exhibit 10.1

 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 

by and between

 

Outlook
Therapeutics, Inc.

 

and

 

GMS VENTURES AND INVESTMENTS

 

Dated April 21, 2022

 

     

     

    

 

TABLE OF CONTENTS

 

Page

 

	Article I Transfer restrictions		1
	 	 	 	 
	 	Section 1.1	General	1
	 	Section 1.2	Legend	2
	 	 	 	 
	Article II REGISTRATION RIGHTS 	2
	 	 	 
	 	Section 2.1	Demand Registration	2
	 	Section 2.2	Piggyback Registration	4
	 	Section 2.3	Expenses	6
	 	Section 2.4	Suspensions	7
	 	Section 2.5	Lock-Up Obligations	8
	 	Section 2.6	Registration Procedures	8
	 	Section 2.7	Effectiveness Period	12
	 	Section 2.8	Indemnification	13
	 	Section 2.9	Free Writing Prospectuses	17
	 	Section 2.10	Information from and Obligations of the Shareholder	17
	 	Section 2.11	Rule 144 Reporting	18
	 	Section 2.12	Termination of Registration Rights	19
	 	Section 2.13	Subsequent Registration Rights	19
	 	Section 2.14	Transfer of Registration Rights.	19
	 	 	 	 
	Article III Right of first offer	19
	 	 	 	 
	 	Section 3.1	General.	19
	 	Section 3.2	Timing and Procedure.	19
	 	Section 3.3	Exercise of Rights.	20
	 	Section 3.4	Closing of a Sale Transaction.	20
	 	Section 3.5	Exclusions	20
	 	 	 	 
	Article IV Preemptive Rights 	21
	 	 	 	 
	 	Section 4.1	General.	21
	 	Section 4.2	Timing and Procedure.	21
	 	Section 4.3	Exercise of Rights.	22
	 	Section 4.4	Closing of Preemptive Issuance.	22
	 	Section 4.5	Exclusions	22
	 	 	 	 
	Article V BOARD OF DIRECTORS 	23
	 	 	 	 
	 	Section 5.1	Initial Shareholder Designees	23
	 	Section 5.2	Right of Shareholder to Nominate Directors.	23
	 	Section 5.3	Election of Shareholder Directors to the Board	24
	 	Section 5.4	Proxy or Information Statement	24
	 	Section 5.5	Qualification and Replacements of Shareholder Directors	24
	 	Section 5.6	Board Committee Representation	25

 

     i

     

    

 

	 	Section 5.7	Rights of the Shareholder Directors	25
	 	Section 5.8	No Duty for Corporate Opportunities	25
	 	 	 	 
	Article VI CERTAIN OTHER AGREEMENTS	26
	 	 	 	 
	 	Section 6.1	Additional Covenants	26
	 	 	 	 
	Article VII TERMINATION 	27
	 	 	 	 
	 	Section 7.1	Termination	27
	 	Section 7.2	Effect of Termination; Survival	27
	 	 	 	 
	Article VIII GENERAL PROVISIONS 	27
	 	 	 	 
	 	Section 8.1	Confidential Information	27
	 	Section 8.2	Fees and Expenses	28
	 	Section 8.3	Notices	28
	 	Section 8.4	Definitions.	29
	 	Section 8.5	Interpretation; Headings	35
	 	Section 8.6	Severability	36
	 	Section 8.7	Entire Agreement; Amendments	36
	 	Section 8.8	Assignment; No Third Party Beneficiaries	36
	 	Section 8.9	Further Assurances	36
	 	Section 8.10	Governing Law; Consent to Jurisdiction; Waiver of Jury Trial	37
	 	Section 8.11	Counterparts	37
	 	Section 8.12	Specific Performance	37
	 	Section 8.13	Waiver	38

 

SCHEDULES

 

Schedule I ‒ Shareholder Representatives

 

    ii

     

    

 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 

This
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT, dated as of April 21, 2022 (this “Agreement”), is by and
between Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), and GMS Ventures and Investments,
a company incorporated under the laws of Cayman Islands (the “Shareholder”). The Shareholder and the Company are referred
to hereinafter each as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS,
the Company, BioLexis Pte Limited, a Singapore private limited company (formerly known as GMS Tenshi Holdings Pte. Limited, “BioLexis”)
and the Shareholder are party to that certain Investor Rights Agreement, dated as of September 11, 2017 (as amended from
time to time, the “Existing Investor Rights Agreement”) with respect to BioLexis’s and the Shareholder’s
ownership of the Capital Stock (as defined below);

 

WHEREAS, the Shareholder
and BioLexis are effecting a restructuring pursuant to which all of the shares of Capital Stock that are owned by BioLexis for the benefit
of Affiliates of the Shareholder are being transferred to the Shareholder, and the Shareholder and its Affiliates will cease to own any
interest in BioLexis;

 

WHEREAS, BioLexis is separately
delivering an agreement to the Company to terminate any rights or obligations of BioLexis pursuant to the Existing Investor Rights Agreement;
and

 

WHEREAS, in connection therewith,
the parties hereto wish to amend and restate the Existing Investor Rights Agreement as provided herein;

 

NOW, THEREFORE, in consideration
of the foregoing and the respective representations, warranties, covenants and agreements set forth in this Agreement and intending to
be legally bound hereby, the Parties agree as follows:

 

Article I

Transfer restrictions

 

Section 1.1     General.

 

(a)            The
Shareholder may freely Transfer any Common Shares to any Person, subject to compliance with applicable Law.

 

(b)            If
the Shareholder Transfers any Common Shares to any Affiliate of the Shareholder (any such Transfer, an “Affiliate Transfer”),
the Shareholder shall promptly notify the Company of such Transfer.

 

    1

     

    

 

(c)            Following
any Affiliate Transfer pursuant to the terms of this Agreement, the Shareholder shall continue to exercise the rights granted to the
Shareholder hereunder on behalf of the Affiliate Shareholder.

 

Section 1.2     Legend.

 

(a)            All
certificates or other instruments representing the Common Shares will bear the following legend:

 

THE SECURITIES REPRESENTED BY THIS
INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT
BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT AND
APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR SUCH LAWS. NOTWITHSTANDING THE FOREGOING,
THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE
SECURITIES.

 

THE SECURITIES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS SET FORTH IN THE AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT, DATED APRIL 21,
2022, BY AND BETWEEN OUTLOOK THERAPEUTICS, INC. AND GMS VENTURE AND INVESTMENTS, AS IT MAY BE AMENDED FROM TIME TO TIME, COPIES
OF WHICH ARE ON FILE WITH AND AVAILABLE FROM THE SECRETARY OF OUTLOOK THERAPEUTICS, INC., WITHOUT COST.

 

(b)            At
the Shareholder’s request, upon advice of the Shareholder’s counsel to the effect that the legend in Section 1.2(a) is
no longer required under the Securities Act and applicable state laws, the Company will promptly take such commercially reasonable actions
as are required to cause such legend to be removed from any certificate or other instrument representing the Common Shares.

 

Article II

REGISTRATION RIGHTS

 

Section 2.1     Demand
Registration.

 

(a)            The
Shareholder may, by providing written notice (a “Demand Registration Request”) to the Company, request to sell all
or a portion of the Registrable Securities Beneficially Owned by the Shareholder and the Affiliate Shareholders, as applicable, pursuant
to a Registration Statement in the manner specified in such notice (a “Demand Registration”). Each Demand Registration
Request shall specify the number of Registrable Securities intended to be offered and sold pursuant to the Demand Registration and the
intended method of disposition thereof, including whether the registration requested is for an underwritten offering. A Demand Registration
shall be effected by way of a Registration Statement on Form S-3 or any similar short-form registration to the extent the Company
is permitted to use such form at such time (or to the extent the Company is not permitted to use such form, on Form S-1 or a similar
long-form registration). A Demand Registration may be, at the option of the Shareholder, (i) a request to file a Registration Statement
(including a Shelf Registration Statement) which will be used to offer the Registrable Securities, or (ii) a request to provide
a prospectus supplement for an already effective Registration Statement. If the Company is then ASR Eligible, the Company shall use its
commercially reasonable efforts to cause the Registration Statement to be an ASRS containing a Prospectus naming the Shareholder as the
selling shareholder and registering the offering and sale of the Registrable Securities by the Shareholder on a delayed or continuous
basis pursuant to Rule 415. The Company shall use its commercially reasonable efforts to cause any Registration Statement (or prospectus
supplement, as applicable) relating to a Demand Registration (A) to be filed with the SEC as promptly as reasonably practicable
following the receipt of the Demand Registration Request, and in no event more than ten (10) days after receipt of a Demand Registration
Request and all necessary information regarding the Shareholder that is required to be included in such Registration Statement (or prospectus
supplement, as applicable) provided pursuant to Section 2.10, (B) to be declared effective by the SEC or otherwise become
effective under the Securities Act as promptly as reasonably practicable after the filing thereof and (C) to remain continuously
effective during the Effectiveness Period.

 

    2

     

    

 

(b)            The
Shareholder shall have the right to request up to a total of two (2) Demand Registrations in any twelve (12)-month period pursuant
to this Section 2.1; provided, that such obligation shall be deemed satisfied (and such request shall count as one
Demand Registration Request for the Shareholder) only when a Registration Statement covering all the Registrable Securities specified
in the Demand Registration Request shall have become effective and (i) if the method of disposition thereof is a firm commitment
Public Offering, all of such Registrable Securities requested to be sold, after giving effect to any Underwriter Cutback (described in
Section 2.1(e)), shall have been sold pursuant thereto, and (ii) in any other case, such Registration Statement shall
have remained effective for the Effectiveness Period. The Shareholder may revoke a request for a Demand Registration by notifying the
Company prior to the effective date of the applicable Registration Statement or the filing of any prospectus supplement with respect
to any particular underwritten offering; provided that such request shall count as one of the Shareholder’s requests for
a Demand Registration unless the Shareholder (A) provides such notice of revocation (x) within five (5) Business Days
after requesting such Demand Registration, or (y) pursuant to Section 2.4(c) as a result of a Notice of Suspension,
or (B) reimburses the Company for all reasonable and documented out-of-pocket expenses (including Registration Expenses) actually
incurred by the Company relating to such Demand Registration.

 

(c)            If
a Demand Registration is a Public Offering, the Shareholder shall have the right to select the investment banking firm(s) to act
as the managing underwriter(s) and counsel for the Shareholder in connection with such offering (including in any underwritten offering
under a Shelf Registration Statement or any Underwritten Block Trade).

 

(d)            In
no event shall any Person, including the Company or any other holder of Capital Stock (other than the Shareholder), be entitled to include
any securities of the Company in any Registration Statement or offering requested pursuant to this Section 2.1 without the
prior written consent of the Shareholder. In the event the managing underwriter shall be of the opinion that the number of shares of
Common Stock requested to be included in a Public Offering pursuant to a Demand Registration Request would adversely affect the marketing
of such offering (including the price at which the securities of the Company may be sold), then the number of securities of the Company
to be included in such underwritten offering will be reduced (an “Underwriter Cutback”), with the securities of the
Company to be included in such offering based on the following priority: (i) first, the number of Shares of Common Stock requested
to be included on behalf of the Shareholder up to the number that, in the opinion of the managing underwriter, would not adversely affect
the marketing of the offering (including the price at which the Shares of Common Stock may be sold); and (ii) second, in addition
to the Shares of Common Stock included pursuant to the preceding clause (i), the number of the securities of the Company requested to
be included, with the prior written permission of the Shareholder, on behalf of each participating Person up to the number that, in the
opinion of the managing underwriter, would not adversely affect the marketing of the offering (including the price at which the securities
of the Company (including the Shares of Common Stock) may be sold). The Company may not file a Registration Statement or commence an
offering of securities on behalf of any of the other holders of Capital Stock until the expiration of the Effectiveness Period of a Demand
Registration.

 

    3

     

    

 

(e)            Notwithstanding
any other provision of this Article II, but subject to Section 2.4, if the Shareholder wishes to engage in an
underwritten block trade or similar transaction or other transaction with a one-day or less marketing period, including overnight bought
deals (collectively, an “Underwritten Block Trade”), pursuant to a Shelf Registration Statement (either through filing
an ASRS or through a take-down from an already effective Shelf Registration Statement), then notwithstanding any other time periods in
this Article II, the Shareholder shall notify the Company of the Underwritten Block Trade three (3) Business Days
prior to the date such Underwritten Block Trade is to commence. As expeditiously as possible, the Company shall use its commercially
reasonable efforts to facilitate such Underwritten Block Trade (which may close as early as three (3) Business Days after the
date it commences). The Shareholder shall use commercially reasonable efforts to work with the Company and the underwriters (including
by disclosing the maximum number of Shares of Common Stock proposed to be the subject of such Underwritten Block Trade) in order to facilitate
preparation of the Registration Statement (including filing of an ASRS), Prospectus and other offering documentation related to the Underwritten
Block Trade.

 

Section 2.2     Piggyback
Registration.

 

(a)            If
the Company at any time following the date hereof proposes to file a registration statement or conduct a securities offering other than
pursuant to this Agreement, including an Underwritten Block Trade, off an already filed Shelf Registration Statement using a prospectus
supplement (such registration statement or prospectus supplement, a “Primary Registration Statement”) for the primary
sale of any securities of the Company (except with respect to registration statements on Form S-4, Form S-8 or another form
not available for registering the Registrable Securities for sale to the public), it will give prompt written notice thereof to the Shareholder
of its intention to do so (such notice to be given not less than fifteen (15) Business Days prior to the anticipated filing date of the
Primary Registration Statement). The Shareholder, to the extent it still holds any Registrable Securities, shall within five (5) Business
Days of receipt of such notice indicate to the Company if it wishes to participate in the offering contemplated by the Primary Registration
Statement and, if so, the number of Registrable Securities it wishes to offer and sell. The Company will use its commercially reasonable
efforts to cause the Registrable Securities as to which inclusion shall have been so requested to be included in the Primary Registration
Statement. The Shareholder shall be entitled to sell the Registrable Securities included in a Primary Registration Statement in accordance
with the method of distribution requested by it; provided that, if the Primary Registration Statement relates to an underwritten
offering, then (i) the Company shall be entitled to select the underwriters in its sole discretion and (ii) the Shareholder
must sell all Registrable Securities included on the Primary Registration Statement in such underwritten offering pursuant to an underwriting
agreement containing terms and conditions that are customary for secondary offerings. In the event that an Underwriter Cutback is required
in the view of the managing underwriter, then the securities of the Company to be included in such underwritten offering will be based
on the following priority: (A) first, the number of securities that the Company seeks to include in the offering, up to the number
that, in the opinion of the managing underwriter, would not adversely affect the marketing of the offering (including the price at which
such securities of the Company may be sold); (B) second, in addition to the securities of the Company included pursuant to the preceding
clause (A), the number of Registrable Securities requested to be included by or on behalf of the Shareholder, up to the number that,
in the opinion of the managing underwriter, would not adversely affect the marketing of the offering (including the price at which the
securities (including the Registrable Securities) may be sold), and (C) third, in addition to securities of the Company included
pursuant to the preceding clause (A) and the Registrable Securities of the Shareholder included pursuant to the preceding clause
(B), the number of securities of the Company requested to be included by any other Person(s) in the offering with the permission
of the Company, up to the number that, in the opinion of the managing underwriter, would not adversely affect the marketing of the offering
(including the price at which the securities of the Company may be sold). The Company may withdraw a Primary Registration Statement prior
to its being declared effective without incurring any liability to the Shareholder and shall not be required to keep a Primary Registration
Statement effective for longer than the period contemplated by the intended manner of distribution for the securities of the Company
to be sold by the Company as described in the Prospectus included in the Primary Registration Statement. The Shareholder may, at least
two (2) Business Days prior to the effective date of a Primary Registration Statement or the filing of any prospectus supplement
with respect to any particular underwritten offering, as applicable, withdraw any Registrable Securities that it had sought to have included
therein, without any liability to the Company or requirement to reimburse for any out-of-pocket expenses of the Company. No registration
of Registrable Securities pursuant to this Section 2.2 shall relieve the Company of its obligations to effect registrations
pursuant to Section 2.1.

 

    4

     

    

 

(b)            If
the Company at any time following the date hereof proposes to file a registration statement or conduct an offering of any of its securities
off an already filed Shelf Registration Statement using a prospectus supplement (such registration statement or prospectus supplement,
a “Secondary Registration Statement”) for the secondary sale of such securities under the Securities Act on behalf
of one or more holders of the securities of the Company other than the Shareholder (the “Requesting Third Party Shareholders”),
the Company will give prompt written notice to the Shareholder of its intention to do so (such notice to be given not less than fifteen (15)
Business Days prior to the anticipated filing date of the Secondary Registration Statement). The Shareholder, to the extent it still
holds Registrable Securities, shall within five (5) Business Days of receipt of such notice indicate to the Company if it wants
to participate in the offering contemplated by the Secondary Registration Statement and, if so, the number of Registrable Securities
it wishes to offer and sell. The Company will use its commercially reasonable efforts to cause the Registrable Securities as to which
inclusion shall have been so requested to be included in the Secondary Registration Statement. The Shareholder shall be entitled to sell
the Registrable Securities included in a Secondary Registration Statement in accordance with the method of distribution requested by
it; provided that, if the Secondary Registration Statement relates to a Public Offering, then (i) the Requesting Third Party
Shareholders (or the Company) shall be entitled to select the underwriters and (ii) the Shareholder must sell all Registrable Securities
included on the Secondary Registration Statement in such Public Offering pursuant to an underwriting agreement on the same terms and
conditions as those applicable to the Requesting Third Party Shareholders. In the event that an Underwriter Cutback is required in the
view of the managing underwriter, then the securities to be included in such Public Offering will be based on the following priority:
(A) first, the number of the securities of the Company that the Requesting Third Party Shareholders seek to include, up to the number
that, in the opinion of the managing underwriter, would not adversely affect the marketing of the offering (including the price at which
such securities may be sold); (B) second, in addition to the securities included pursuant to the preceding clause (A), the
number of Registrable Securities requested to be included by or on behalf of the Shareholder, up to the number that, in the opinion of
the managing underwriter, would not adversely affect the marketing of the offering (including the price at which the securities (including
the Registrable Securities) may be sold); (C) third, in addition to the securities included pursuant to the preceding clauses (A) and
(B), the number of securities sought to be included by the Company, up to the number that, in the opinion of the managing underwriter,
would not adversely affect the marketing of the offering (including the price at which the securities may be sold); and (D) fourth,
in addition to the securities included pursuant to the preceding clauses (A), (B) and (C), the number of securities sought to be
included by any other Persons permitted to participate in such underwritten offering, up to the number that, in the opinion of the managing
underwriter, would not adversely affect the marketing of the offering (including the price at which the securities may be sold). Requesting
Third Party Shareholders or the Company may withdraw a Secondary Registration Statement prior to its being declared effective without
incurring any liability to the Shareholder, and the Company shall not be required to keep a Secondary Registration Statement effective
for longer than the period contemplated by the intended manner of distribution for the sale of the securities by the Requesting Third
Party Shareholders as described in the Prospectus included in the Secondary Registration Statement. The Shareholder may, at least two
(2) Business Days prior to the effective date of a Secondary Registration Statement or the filing of any prospectus supplement with
respect to any particular underwritten offering, as applicable, withdraw any Registrable Securities that it had sought to have included
therein, without any liability to the Company or any other Person or requirement to reimburse for any out-of-pocket expenses of the Company.
Notwithstanding the foregoing, this Section 2.2(b) shall not be applicable to the conversion of existing resale shelf
registration statements on Form S-1 to Form S-3 or to the registration of additional securities for resale to the extent the
Company is required to effect such registration under agreements that exist as of the date hereof.

 

    5

     

    

 

Section 2.3     Expenses.
Except as specifically provided herein, all Registration Expenses incurred in connection with the registration or offering and sale of
the Registrable Securities shall be borne by the Company and all Selling Expenses shall be borne by the Shareholder; provided
that, notwithstanding anything herein to the contrary, in no event shall the Shareholder bear or be responsible for any fees or expenses
of the Company’s legal counsel in connection with the registration or offering and sale of Registrable Securities.

 

    6

     

    

 

Section 2.4     Suspensions.

 

(a)            Notwithstanding
anything to the contrary contained in this Agreement, the Company shall be entitled, by providing written notice (a “Notice
of Suspension”) to the Shareholder, to delay the filing or effectiveness of a Registration Statement or require the Shareholder
to suspend the use of the Prospectus for sales of Registrable Securities under an effective Registration Statement for a reasonable period
of time not to exceed sixty (60) consecutive days or ninety (90) days in the aggregate in any twelve (12)-month period (a “Suspension
Period”) if the Company Board (or the executive committee thereof) determines in good faith that such filing, effectiveness
or use would (i) require the public disclosure of material non-public information concerning any material transaction or negotiations
involving the Company that would interfere with such material transaction or negotiations or (ii) otherwise materially interfere
with material financing plans, acquisition activities or business activities of the Company; provided, that if at the time of
receipt of such notice by the Shareholder, the Shareholder shall have sold all or a portion of the Registrable Securities (or have signed
a firm commitment underwriting agreement with respect to the sale of such Registrable Securities) pursuant to an effective Registration
Statement and the reason for the Suspension Period is not of a nature that would require a post-effective amendment to the Registration
Statement, then the Company shall use its commercially reasonable efforts to take such action as to eliminate any restriction imposed
by federal securities Laws by the time such Registrable Securities are scheduled to be delivered. Immediately upon receipt of a Notice
of Suspension, the Shareholder shall discontinue the disposition of Registrable Securities under an effective Registration Statement
and Prospectus relating thereto until the Suspension Period is terminated.

 

(b)            The
Company agrees that it will terminate any Suspension Period as promptly as reasonably practicable and will promptly notify in writing
the Shareholder, to the extent it still holds Registrable Securities, of such termination. After the expiration of any Suspension Period
in the case of an effective Registration Statement, and without the need for any further request from the Shareholder, the Company shall,
as promptly as reasonably practicable, prepare a post-effective amendment or supplement to such Registration Statement, the relevant
Prospectus, or any document incorporated therein by reference, or file any other required document so that, as thereafter delivered to
purchasers of the Registrable Securities included therein, the Registration Statement or the Prospectus, as applicable, will not include
an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading.

 

(c)            If
a Suspension Period occurs during the Effectiveness Period for a Registration Statement, such Effectiveness Period shall be extended
for a number of days equal to the total number of days during which the distribution of Registrable Securities is suspended under this
Section 2.4. If the Company notifies the Shareholder of a Suspension Period with respect to a Registration Statement requested
pursuant to Section 2.1 (including a Demand Registration Request) that has not yet been filed or declared effective, (i) the
Shareholder may by notice to the Company withdraw such request without such request counting as a Demand Registration Request and (ii) the
Shareholder will not be obligated to reimburse the Company for any of its out-of-pocket expenses, including Registration Expenses.

 

    7

     

    

 

Section 2.5     Lock-Up
Obligations. To the extent reasonably requested by a managing underwriter, if any, of any underwritten Public Offering (including
any Underwritten Block Trade) of the securities of the Company pursuant to Section 2.1 or Section 2.2, the Company
hereby agrees, (i) not to (A) offer for sale, sell, pledge, or otherwise dispose of (or enter into any transaction that is
designed to, or could be expected to, result in the disposition by any Person at any time in the future of) any shares of common stock
of the Company or any other form of Capital Stock (collectively, the “Restricted Stock”) (other than the grant of
equity awards with respect to, or the issuance of shares of Capital Stock under, any of the Company’s bona fide equity incentive
plans in existence at the start of the lock-up period specified in this Section 2.5), (B) enter into any swap or other
derivatives transaction that transfers to another Person, in whole or in part, any of the economic benefits or risks of ownership of
Restricted Stock, whether any such transaction described in clause (A) above or this clause (B) is to be settled
by delivery of Restricted Stock or other securities, in cash or otherwise, or (C) publicly disclose the intention to do any of the
foregoing, in each case, for a period specified by such managing underwriter or co-managing underwriter but no more than the ten (10) days
prior to and the ninety (90) days (or one hundred and eighty (180) days if reasonably requested by the managing underwriters) following
the pricing date of the Public Offering of such securities.

 

Section 2.6     Registration
Procedures. Whenever the Shareholder requests that any Registrable Securities be registered pursuant to Section 2.1 or
Section 2.2, subject to the provisions of those Sections, the Company will use its commercially reasonable efforts to effect
the registration and the offer and sale of such Registrable Securities in accordance with the intended method of disposition thereof
as soon as reasonably practicable, and shall, in connection with any such request:

 

(a)            prepare
and promptly file with the SEC a Registration Statement (or a prospectus supplement, as applicable) with respect to such securities and
use its commercially reasonable efforts to cause such Registration Statement to become effective as soon as practicable thereafter and
remain effective for the period of the distribution contemplated thereby (but in no event longer than the Effectiveness Period) and at
least three (3) Business Days (or, with regard to any Underwritten Block Trade, as soon as reasonably practicable) before filing
a Registration Statement or Prospectus or any amendments or supplements thereto (but, for the avoidance of doubt, not any documents incorporated
by reference therein), or any related free writing prospectus, furnish to the Shareholder and the underwriter(s), if any, copies of all
such documents proposed to be filed, and provide the Shareholder with the opportunity to object to any information pertaining to it and
the plan of distribution that is contained therein;

 

(b)            (i) prepare
and file with the SEC such amendments and supplements to such Registration Statement and the Prospectus used in connection therewith
and such free writing prospectuses and Exchange Act reports as may be necessary to keep such Registration Statement effective for the
period specified in paragraph (a) above and comply with the provisions of the Securities Act with respect to the disposition
of all Registrable Securities covered by such Registration Statement and any prospectus so supplemented to be filed pursuant to Rule 424
under the Securities Act in accordance with the Shareholder’s intended method of disposition set forth in such Registration Statement
for such period, and (ii) provide reasonable notice to the Shareholder and the managing underwriter(s), if any, to the extent that
the Company determines that a post-effective amendment to a registration statement would be appropriate;

 

    8

     

    

 

(c)            furnish
to the Shareholder and the underwriter(s), if any, without charge, such number of copies of the Registration Statement, each amendment
and supplement thereto, the Prospectus included therein (including each preliminary prospectus) and any other prospectuses filed under
Rule 424 and each free writing prospectus as such Persons reasonably may request in order to facilitate the public sale or other
disposition of the Registrable Securities covered by such Registration Statement;

 

(d)            use
its commercially reasonable efforts to register or qualify the Registrable Securities covered by such Registration Statement under the
securities or “blue sky” Laws of such jurisdictions as the Shareholder or, in the case of a Public Offering, the managing
underwriter reasonably shall request and do any and all other acts and things which may be reasonably necessary or advisable to enable
the Shareholder to consummate the disposition in such jurisdictions of the Registrable Securities Beneficially Owned by it; provided,
however, that the Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation
in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction;

 

(e)            promptly
notify the Shareholder and each managing underwriter, if any: (i) when the Registration Statement, any pre-effective amendment,
the Prospectus or any prospectus supplement related thereto, any post-effective amendment to the Registration Statement or any free writing
prospectus has been filed with the SEC and, with respect to the Registration Statement or any post-effective amendment, when the same
has become effective; (ii) of any request by the SEC or state securities authority for amendments or supplements to the Registration
Statement or the Prospectus related thereto or for additional information, including copies of any and all transmittal letters and other
correspondence with the SEC and all correspondence (including comment letters and a copy of the Company’s draft responses thereto),
from the SEC to the Company relating to such Registration Statement or any Prospectus or any amendment or supplement thereto (but not,
for the avoidance of doubt, any documents incorporated by reference therein); (iii) of the issuance by the SEC of any stop order
suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; or (iv) of the
receipt by the Company of any notification with respect to the suspension of the qualification of any Registrable Securities for sale
under the securities or state “blue sky” Laws of any jurisdiction or the initiation of any proceeding for such purpose.

 

(f)            if
at any time (i) any event or development shall occur or condition shall exist as a result of which the Disclosure Package, as then
amended or supplemented, would include any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements therein, in the light of the circumstances existing when the Disclosure Package is delivered to a purchaser, not
misleading, or (ii) it is necessary to amend or supplement the Disclosure Package to comply with Law, the Company will promptly
notify the Shareholder and each managing underwriter, if any, and promptly prepare and file with the SEC (to the extent required) and
furnish to the Shareholder and each underwriter, if any, such amendments or supplements to the Disclosure Package as may be necessary
so that the statements in the Disclosure Package, as so amended or supplemented, will not, in the light of the circumstances existing
when the Disclosure Package is delivered to a purchaser, be misleading, or so that the Disclosure Package will comply with Law;

 

    9

     

    

 

(g)            use
its commercially reasonable efforts to make generally available to the Shareholder, as soon as reasonably practicable, an earnings statement
covering the period of at least twelve (12) months beginning with the first day of the Company’s first full calendar quarter after
the effective date of a Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the
Securities Act and Rule 158;

 

(h)            use
its commercially reasonable efforts to list the Registrable Securities covered by such Registration Statement on the Nasdaq Global Market
(“Nasdaq”) or any other national securities exchange on which the Common Stock is listed;

 

(i)            use
its commercially reasonable efforts to cause its officers, employees and independent public accountants (in the case of the independent
public accountants, subject to any applicable accounting guidance regarding their participation in the offering or the due diligence
process) to participate in, make themselves reasonably available, supply such information as may reasonably be requested and to otherwise
facilitate and cooperate with the preparation of the Registration Statement and Prospectus and any amendments or supplements thereto
(including participating in meetings, marketing activities, investor calls, drafting sessions, due diligence sessions and rating agency
presentations) taking into account the Company’s reasonable business needs (it being acknowledged that the activities specified
in this Section 2.6(i) may be required approximately once in every ninety (90) calendar day period depending on market
conditions and other factors and subject to the proper exercise of a demand hereunder)

 

(j)            provide
a transfer agent and registrar for all such Registrable Securities not later than the effective date of such Registration Statement (or
the pricing date of the relevant offering);

 

(k)            immediately
notify the Shareholder, at any time when a Prospectus is required to be delivered under the Securities Act, of the occurrence or happening
of any event as a result of which the Prospectus contained in a Registration Statement, as then in effect, includes an untrue statement
of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading
in light of the circumstances then existing, and at the request of the Shareholder, as promptly as reasonably practicable prepare and
furnish to the Shareholder a reasonable number of copies of a supplement to or an amendment of such Prospectus as may be necessary so
that, as thereafter delivered, such Prospectus shall not include an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing;

 

(l)            if
the offering is underwritten, then at the request of the Shareholder, (i) enter into such customary agreements (including underwriting
agreements in customary form) and take all such other actions as the Shareholder reasonably requests in order to expedite or facilitate
the disposition of such Registrable Securities (including making executive officers of the Company available, on reasonable advance notice,
to participate in, and cause them to cooperate with the underwriters in connection with, “road-shows” and underwriter due
diligence calls), and (ii) use commercially reasonable efforts to furnish on the date that Registrable Securities are delivered
to the underwriters for sale: (A) an opinion of counsel to the Company, dated such date, addressed to the underwriters and to the
Shareholder, covering such matters as are typically included in an opinion to underwriters for a comparable secondary transaction, including
stating that such Registration Statement has become effective under the Securities Act and that (x) to the knowledge of such counsel,
no stop order suspending the effectiveness thereof has been issued and no proceedings for that purpose have been instituted or are pending
or contemplated under the Securities Act, and (y) the Registration Statement, the related Prospectus and each amendment or supplement
thereof comply as to form in all material respects with the requirements of the Securities Act (except that such counsel need not express
any opinion as to financial statements or financial data contained therein), (B) a letter dated such date from the independent public
accountants retained by the Company (and brought down to the closing under the underwriting agreement), addressed to the underwriters
and to the Shareholder, stating that they are independent public accountants within the meaning of the Securities Act and the applicable
rules and regulations adopted by the SEC thereunder, and otherwise in customary form and covering such financial and accounting
matters as are customarily covered by letters of the independent certified public accountants delivered in connection with a comparable
secondary transaction, including that, in the opinion of such accountants, the financial statements of the Company included in the Registration
Statement or the Prospectus, or any amendment or supplement thereof, comply as to form, in all material respects, with the applicable
accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including information
as to the period ending no more than three (3) Business Days prior to the date of such letter) with respect to such registration
or offering as such underwriters or the Shareholder may reasonably request and (C) a comfort letter similar to the letter described
in clause (B) from the auditors of any other financial statements, if any, included or required to be included in the Registration
Statement or Prospectus or any amendment or supplement thereto (including financial statements of entities acquired by the Company);

 

    10

     

    

 

(m)           use
its commercially reasonable efforts to cooperate with the Shareholder and each underwriter in the disposition of the Registrable Securities
covered by such Registration Statement;

 

(n)            in
connection with the preparation and filing of each Registration Statement registering Registrable Securities under the Securities Act,
and before filing any such Registration Statement or any other document in connection therewith, give reasonable consideration to the
inclusion in such documents of any comments reasonably and timely made by the Shareholder or its legal counsel; participate in, and make
documents available for, the reasonable and customary due diligence review of underwriters during normal business hours, on reasonable
advance notice and without undue burden or hardship on the Company; provided that (i) any party receiving confidential materials
shall execute a confidentiality agreement on customary terms if reasonably requested by the Company and (ii) the Company may in
its sole discretion restrict access to competitively sensitive or legally privileged documents or information;

 

(o)            cooperate
with the Shareholder and each underwriter participating in the disposition of the Registrable Securities and their respective counsel
in connection with any filings required to be made with FINRA;

 

(p)            use
its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness of a Registration
Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction and, if such an order
or suspension is issued, to use its commercially reasonable efforts to obtain the withdrawal of such order or suspension at the earliest
possible moment and to notify the Shareholder of the issuance of such order and the resolution thereof or its receipt of actual notice
of the initiation or threat of any proceeding for such purpose;

 

    11

     

    

 

(q)            otherwise
use its commercially reasonable efforts to comply with the Securities Act, the Exchange Act and any other applicable rules and regulations
of the SEC and reasonably cooperate with the Shareholder in the disposition of its Registrable Securities in accordance with the method
of distribution described in the Prospectus included in any Registration Statement, such cooperation to include the endorsement and transfer
of any certificates representing Registrable Securities (or a book-entry transfer to similar effect) transferred in accordance with this
Agreement and delivery of any necessary instructions or opinions to the Company’s transfer agent in order to cause the transfer
agent to allow the shares of Common Stock to be sold from time to time as permitted by Law;

 

(r)            take
all reasonable action to ensure that any Free Writing Prospectus utilized in connection with any registration covered by Section 2.1
or Section 2.2 complies in all material respects with the Securities Act, is filed in accordance with the Securities
Act to the extent required thereby, is retained in accordance with the Securities Act to the extent required thereby, will not conflict
with a related Prospectus, prospectus supplement and related documents and, when taken together with the related Prospectus, prospectus
supplement and related documents, will not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading;

 

(s)            use
its commercially reasonable efforts to cooperate with the managing underwriters, if any, the Shareholder and their respective counsel
in connection with the preparation and filing of any applications, notices, registrations and responses to requests for additional information
with FINRA, Nasdaq or any other national securities exchange on which the shares of Common Stock are listed; and

 

(t)            pay
the applicable filing fees covering the Registrable Securities in compliance with the SEC rules and to file such amendments or subsequent
registration statements as may be required to maintain an effective registration statement for the relevant Effectiveness Period.

 

Section 2.7     Effectiveness
Period. For purposes of this Article II, the period of distribution of Registrable Securities in a firm commitment Public
Offering shall be deemed to extend until each underwriter participating in the offering has completed the distribution of all securities
of the Company purchased by it, and the period of distribution of Registrable Securities pursuant to a Registration Statement for any
other manner of distribution shall be deemed to extend until the later of (i) the sale of all Registrable Securities covered thereby
and (ii) ninety (90) days after the effective date thereof (such period, including any extension pursuant to Section 2.4,
the “Effectiveness Period”).

 

    12

     

    

 

Section 2.8     Indemnification.

 

(a)            Indemnification
Rights.

 

(i)        In
the event of any registration or other offer and sale of any securities of the Company under the Securities Act pursuant to this Article II,
the Company shall indemnify and hold harmless the Shareholder and each Person, if any, that controls the Shareholder within the meaning
of Section 15 of the Securities Act (each a “controlling person”), their respective officers, directors, employees,
stockholders, general and limited partners, members, Representatives and Affiliates, and each controlling person of each Affiliate of
any of the foregoing Persons (each, a “Shareholder Registration Rights Indemnitee”), to the fullest extent lawful,
from and against any and all Damages caused by, relating to, arising out of, or in connection with (A) any untrue statement of material
fact (or alleged untrue statement of a material fact) contained in any Disclosure Package, any Registration Statement, any Prospectus
(including any preliminary Prospectus), any Free Writing Prospectus, or in any amendment or supplement thereto, or (B) any omission
or alleged omission to state therein any material fact required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading; provided that the Company shall not be liable to a Shareholder
Registration Rights Indemnitee to the extent that any such Damages are directly caused by any untrue statement or omission (or alleged
untrue statement or omission) made in such Disclosure Package, Registration Statement, Prospectus (including any preliminary Prospectus),
Free Writing Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information about the
Shareholder furnished to the Company by or on behalf of the Shareholder expressly for use therein. This indemnity agreement shall be
in addition to any liability which the Company may otherwise have. Such indemnity and reimbursement of expenses shall remain in full
force and effect regardless of any investigation made by or on behalf of any Shareholder Registration Rights Indemnitee and shall survive
the transfer of securities by the Shareholder.

 

(ii)       The
Shareholder shall indemnify and hold harmless the Company and each of its officers who execute any of the Company’s filings with
the SEC pursuant to the Exchange Act or the Securities Act, its directors, officers and employees (each, a “Company Registration
Rights Indemnitee”), to the fullest extent lawful, from and against any and all Damages directly caused by, relating to, arising
out of, or in connection with (A) any untrue statement of material fact (or alleged untrue statement of a material fact) contained
in any Disclosure Package, any Registration Statement, any Prospectus (including any preliminary Prospectus), any Free Writing Prospectus
or in any amendment or supplement thereto or (B) any omission (or alleged omission) to state therein any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading,
in each case, to the extent that such untrue statement or omission was made in reliance upon and in conformity with written information
furnished to the Company by or on behalf of the Shareholder expressly for use therein; provided, however, that in no event
shall the obligations of the Shareholder hereunder exceed the net proceeds received by it from the sale of its Registrable Securities
related to the matter in which Damages are sought. The Company and the Shareholder hereby acknowledge and agree that, unless otherwise
expressly agreed to in writing by the Shareholder to the contrary, for all purposes of this Agreement, the only information furnished
or to be furnished to the Company for use in any registration statement, preliminary, final or summary prospectus or amendment or supplement
thereto, or any free writing prospectus, are statements specifically relating to (w) the beneficial ownership of the Capital Stock
by the Shareholder and its Affiliates as disclosed in the section of such document entitled “Selling Shareholders” or “Principal
and Selling Shareholders” or other variations thereof, (x) the name and address of the Shareholder, (y) any information
provided by or on behalf of the Shareholder for any plan of distribution prepared in accordance with Item 508 of Regulation S-K and (z) any
free writing prospectus prepared by the Shareholder for purposes of a specific offering. Such indemnity and reimbursement of expenses
shall remain in full force and effect regardless of any investigation made by or on behalf of a Company Registration Rights Indemnitee
and shall survive the Transfer of such securities by the Shareholder. Such indemnity and reimbursement of expenses shall remain in full
force and effect regardless of any investigation made by or on behalf of a Company Registration Rights Indemnitee and shall survive the
Transfer of such securities by the Shareholder.

 

    13

     

    

 

(iii)       If
the indemnification provided for in Section 2.8(a)(i) or Section 2.8(a)(ii) is unavailable to a Shareholder
Registration Rights Indemnitee or a Company Registration Rights Indemnitee, as applicable, with respect to any Damages referred to therein
or is unenforceable or insufficient to hold a Shareholder Registration Rights Indemnitee or Company Registration Rights Indemnitee, as
applicable, harmless as contemplated therein, then the Company or the Shareholder, as applicable, in lieu of indemnifying such Shareholder
Registration Rights Indemnitee or Company Registration Rights Indemnitee, as applicable, shall contribute to the amount paid or payable
by such Shareholder Registration Rights Indemnitee or Company Registration Rights Indemnitee, as applicable, as a result of such Damages
in such proportion as is appropriate to reflect the relative fault of such Shareholder Registration Rights Indemnitee or Company Registration
Rights Indemnitee, as applicable, on the one hand, and the Company or the Shareholder, as applicable, on the other hand, in connection
with the statements or omissions which resulted in such Damages as well as any other relevant equitable considerations. The relative
fault of the Company or the Shareholder, as applicable, on the one hand, and of a Shareholder Registration Rights Indemnitee or Company
Registration Rights Indemnitee, as applicable, on the other hand, shall be determined by reference to, among other factors, whether the
untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by or on behalf of the Company or the Shareholder, as applicable, and the parties’ relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission; the Company and the Shareholder agree that it would
not be just and equitable if contribution pursuant to this Section 2.8(a)(iii) were determined by pro rata allocation
or by any other method of allocation that does not take account of the equitable considerations referred to in this Section 2.8(a)(iii).
No Shareholder Registration Rights Indemnitee or Company Registration Rights Indemnitee guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from the Company or the Shareholder,
as applicable, if the Company or the Shareholder, as applicable, was not guilty of such fraudulent misrepresentation. Notwithstanding
anything herein to the contrary, in no event shall the liability of the Shareholder pursuant to this Section 2.8(a)(iii) be
greater in amount than the amount of net proceeds received by it from the sale of such Registrable Securities related to the matter in
which indemnification or contribution for Damages are sought.

 

    14

     

    

 

(b)            Notice
of Reg Rights Claim.

 

(i)        As
used in this Agreement, the term “Reg Rights Claim” means a claim for indemnification or contribution by or on behalf
of any Company Registration Rights Indemnitee or Shareholder Registration Rights Indemnitee, as the case may be, for Damages under Section 2.8(a) (such
Person making a Reg Rights Claim, a “Reg Rights Indemnified Person”). The Company (for its own Damages or for the
Damages incurred by any other Company Registration Rights Indemnitee) or the Shareholder (for its own Damages or for the Damages incurred
by any other Shareholder Registration Rights Indemnitee), as applicable, shall give notice of a Reg Rights Claim under this Agreement
pursuant to a written notice of such Reg Rights Claim executed by the Company or the Shareholder, as applicable (a “Notice of
Reg Rights Claim”), and delivered to the Company or the Shareholder, as applicable (such receiving party, the “Reg
Rights Indemnifying Person”), promptly after such Reg Rights Indemnified Person becomes aware of the existence of any potential
claim by such Reg Rights Indemnified Person for indemnification arising out of or resulting from any item indemnified pursuant to the
terms of Section 2.8(a)(i) or Section 2.8(a)(ii); provided that the failure to timely give such notice
shall not limit or reduce the Reg Rights Indemnified Person’s right to indemnification hereunder unless (and then only to the extent
that) the Reg Rights Indemnifying Person’s defense of such Reg Rights Claim is materially and adversely prejudiced thereby.

 

(ii)       Each
Notice of Reg Rights Claim shall: (A) state the aggregate amount (where practicable) that the Reg Rights Indemnified Person has
incurred or paid in Damages arising from such Reg Rights Claim (which amount may include the amount of Damages claimed by a third party
in an action (a “Third-Party Reg Rights Claim”) brought against such Reg Rights Indemnified Person based on alleged
facts, which if true, would give rise to liability for Damages to such Reg Rights Indemnified Person); and (B) contain a brief description,
in reasonable detail (to the extent reasonably available to the Reg Rights Indemnified Person) of the facts, circumstances or events
giving rise to the alleged Damages based on the Reg Rights Indemnified Person’s good faith belief and knowledge thereof, including
the identity and address of any third party claimant (to the extent reasonably available to the Reg Rights Indemnified Person).

 

(c)            Defense
of Third-Party Reg Rights Claims.

 

(i)        Subject
to the provisions hereof, the applicable Reg Rights Indemnifying Person shall have the right (at its own expense) to elect to defend
and assume control of the defense of any Third-Party Reg Rights Claim on behalf of a Reg Rights Indemnified Person, utilizing legal counsel
reasonably acceptable to such Reg Rights Indemnified Person. In the event such election is made, the Reg Rights Indemnified Person (unless
itself controlling the Third-Party Reg Rights Claim in accordance with this Section 2.8(c)) may participate, through counsel
of its own choice and, except as provided herein, at its own expense, in the defense of any Third-Party Reg Rights Claim. The reasonable
and documented costs and expenses incurred by the Reg Rights Indemnifying Person in connection with such defense (including reasonable
attorneys’ fees, other professionals’ and experts’ fees and court or arbitration costs) shall be paid by the Reg Rights
Indemnifying Person.

 

    15

     

    

 

(ii)       A
Reg Rights Indemnifying Person shall not be entitled to assume control of such defense, and the applicable Reg Rights Indemnified Person
may assume the control and defense thereof, at the sole expense of the applicable Reg Rights Indemnifying Person, if (A) the Reg
Rights Claim relates to, or arises in connection with, any criminal or governmental proceeding, action, indictment, allegation or investigation,
(B) the Reg Rights Claim seeks an injunction against the Reg Rights Indemnified Person, to the extent that such defense relates
to the claim for such injunction, (C) a conflict of interest between the Reg Rights Indemnifying Person and the Reg Rights Indemnified
Person exists with respect to the Reg Rights Claim or the Reg Rights Indemnifying Person and the Reg Rights Indemnified Person have one
or more conflicting defenses, in the reasonable view of their respective counsel, or (D) the Reg Rights Indemnifying Person has
elected to have the Reg Rights Indemnified Person defend, or assume the control and defense of, a Third-Party Reg Rights Claim in accordance
with this Section 2.8(c); provided that in no event shall the Reg Rights Indemnifying Person be liable for the fees
and expenses of more than one separate counsel for all Reg Rights Indemnified Persons, which counsel shall be selected by the Shareholder
(in the case of the Shareholder Registration Rights Indemnitees) or by the Company (in the case of the Company Registration Rights Indemnitees).

 

(iii)      Any
party controlling the defense of any Third-Party Reg Rights Claim pursuant hereto shall: (A) conduct the defense of such Third-Party
Reg Rights Claim with reasonable diligence and keep the other parties reasonably informed of material developments in the Third-Party
Reg Rights Claim at all stages thereof, (B) as promptly as reasonably practicable, submit to the other parties copies of all pleadings,
responsive pleadings, motions and other similar legal documents and papers received or filed in connection therewith, (C) permit
the other parties and their counsel to confer on the conduct of the defense thereof, and (D) permit the other parties and their
counsel an opportunity to review all legal papers to be submitted prior to their submission. The parties not controlling the defense
will render to the party controlling the defense such assistance as may be reasonably required in order to insure the proper and adequate
defense thereof and shall furnish such records, information and testimony and attend such conferences, discovery proceedings, hearings,
trials and appeals as may be reasonably requested by the party controlling the defense in connection therewith. The Reg Rights Indemnifying
Person shall reimburse the parties not controlling the defense for any reasonable and documented costs and expenses incurred in connection
with providing such assistance. Notwithstanding anything to the contrary in this Agreement, no Party shall be required to disclose any
information to the other Party or its Representatives, if doing so would be reasonably expected to violate any Law to which such Party
is subject or could jeopardize (in the reasonable discretion of the disclosing Party) any attorney-client privilege available with respect
to such information.

 

    16

     

    

 

(iv)      If
the Reg Rights Indemnifying Person controls the defense of and defends any Third-Party Reg Rights Claim under this Section 2.8(c),
the Reg Rights Indemnifying Person shall have the right to effect a settlement of such Third-Party Reg Rights Claim on the Reg Rights
Indemnified Person’s behalf and without the consent of the Reg Rights Indemnified Person; provided that (A) such settlement
shall not involve any injunctive relief binding upon the Reg Rights Indemnified Person or any of its Affiliates, and (B) such settlement
expressly and unconditionally releases the Reg Rights Indemnified Person and the other applicable Reg Rights Indemnified Persons (that
is, each of the Company Registration Rights Indemnitees, if the Reg Rights Indemnified Person is a Company Registration Rights Indemnitee,
and each of the Shareholder Registration Rights Indemnitees, if the Reg Rights Indemnified Person is a Shareholder Registration Rights
Indemnitee) from any and all liabilities with respect to such Third-Party Reg Rights Claim, with prejudice. If the Reg Rights Indemnified
Person controls the defense of and defends any Third-Party Reg Rights Claim under this Section 2.8(c), the Reg Rights Indemnified
Person shall have the right to effect a settlement of such Third-Party Reg Rights Claim only with the consent of the Reg Rights Indemnifying
Person (which consent shall not be unreasonably withheld, conditioned or delayed). No settlement by the Reg Rights Indemnified Person
of such Third-Party Reg Rights Claim effected in accordance with this Section 2.8(c) shall limit or reduce the right
of any Reg Rights Indemnified Person to indemnity hereunder for all Damages they may incur arising out of or resulting from the Third-Party
Reg Rights Claim, to the extent such Damages are indemnifiable hereunder. As used in this Section 2.8(c)(iv), the term “settlement”
refers to any consensual resolution of the claim in question, including by consent decree or by permitting any judgment or other resolution
of a claim to occur without disputing the same, and the term “settle” has a corresponding meaning.

 

Section 2.9     Free
Writing Prospectuses. Except for a Prospectus relating to Registrable Securities included in a Registration Statement, an “issuer
free writing prospectus” (as defined in Rule 433 under the Securities Act) prepared by the Company or other materials prepared
by Company, the Shareholder represents and agrees that it (a) will not make any offer relating to the Registrable Securities that
would constitute an issuer free writing prospectus or that would otherwise constitute a Free Writing Prospectus, and (b) will not
distribute any written materials in connection with the offer or sale pursuant to a Registration Statement of Registrable Securities,
in each case, without the prior written consent of the Company and, in connection with any Public Offering, the underwriters.

 

Section 2.10   Information
from and Obligations of the Shareholder. The Company’s obligation to include the Shareholder’s Registrable Securities
in any Registration Statement or Prospectus is contingent upon the Shareholder:

 

(a)            furnishing
to the Company in writing information with respect to its ownership of Registrable Securities and the intended method of disposition
of its Registrable Securities as the Company may reasonably request or as may be required by Law for use in connection with a Registration
Statement or Prospectus (or any amendment or supplement thereto) and all information required to be disclosed in order to make the information
the Shareholder previously furnished to the Company not contain a material misstatement of fact or necessary to cause such Registration
Statement or Prospectus (or amendment or supplement thereto) not to omit a material fact with respect to the Shareholder necessary in
order to make the statements therein not misleading;

 

    17

     

    

 

(b)            complying
with (i) the Securities Act and the Exchange Act, (ii) all applicable state securities Laws, (iii) the rules of any
securities exchange or trading market on which the shares of Common Stock are listed or traded, and (iv) all other applicable regulations,
in each case, in connection with the registration and the disposition of Registrable Securities;

 

(c)            following
its actual knowledge thereof, notifying the Company of the occurrence of any event that makes any statement made in a Registration Statement,
Prospectus, issuer free writing prospectus or other Free Writing Prospectus regarding the Shareholder untrue in any material respect
or that requires the making of any changes in a Registration Statement, Prospectus, issuer free writing prospectus or other Free Writing
Prospectus so that, in such regard, it will not contain any untrue statement of a material fact or omit any material fact required to
be stated therein or necessary to make the statements not misleading;

 

(d)            providing
the Company with such information as may be required to enable the Company to prepare a supplement or post-effective amendment to any
such Registration Statement or a supplement to such Prospectus or Free Writing Prospectus;

 

(e)            using
commercially reasonable efforts to cooperate with the Company in preparing the applicable Registration Statement and any related Prospectus;
and

 

(f)            furnishing
the Company with all information required to be included in such Registration Statement or Prospectus by applicable securities Laws in
connection with the disposition of such Registrable Securities as the Company reasonably requests.

 

Section 2.11     Rule 144
Reporting.

 

(a)            With
a view to making available to the Shareholder the benefits of certain rules and regulations of the SEC which may permit the sale
of the Registrable Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to make
and keep available adequate current public information, as defined in Rule 144(c), including all periodic and annual reports and
other documents (other than Form 8-K reports) required of the Company under Sections 13 or 15(d) of the Exchange Act,
and so long as the Shareholder Beneficially Owns any Registrable Securities or securities convertible into or exercisable for Registrable
Securities, furnish to the Shareholder forthwith upon request: a written statement by the Company as to its compliance with the reporting
requirements of Rule 144, and of the Exchange Act; a copy of the most recent annual or quarterly report of the Company; and such
other reports and documents as the Shareholder may reasonably request in availing itself of any rule or regulation of the SEC allowing
it to sell any Registrable Securities without registration.

 

(b)            For
the avoidance of doubt, the Shareholder may sell any Common Shares in compliance with Rule 144, regardless of whether a Registration
Statement has been filed with the SEC or is effective. The Company agrees to (i) make and keep public information available as those
terms are understood and defined in Rule 144, (ii) use its commercially reasonable efforts to file with the SEC in a timely
manner all reports and other documents required of the Company under the Securities Act and the Exchange Act, and (iii) so long
as the Shareholder owns any Common Shares, furnish to the Shareholder upon request, a written statement by the Company as to its compliance
with the reporting requirements of Rule 144, and of the Securities Act and the Exchange Act.

 

    18

     

    

 

Section 2.12  Termination
of Registration Rights. Notwithstanding anything to the contrary contained herein, the registration rights granted under this Article II
terminate and are of no further force and effect (other than Section 2.3 and Section 2.8), on the date on
which there cease to be any Registrable Securities.

 

Section 2.13   Subsequent
Registration Rights. The Company shall not (a) grant any registration rights to third parties which are more favorable than,
or inconsistent with, the rights granted hereunder, or (b) enter into any agreement, take any action, or permit any change to occur,
with respect to its securities, that violates or subordinates the rights expressly granted to the Shareholder in this Article II.

 

Section 2.14   Transfer
of Registration Rights. The Shareholder shall have the right to Transfer to any Person (such Person, a “Transferee Shareholder”),
directly or indirectly, by written agreement, any or all of its rights and obligations granted under this Article II in connection
with a Transfer of all or a portion of its Registrable Securities to such Person. Such Transferee Shareholder shall, following such Transfer,
become responsible for all obligations applicable to the Shareholder under this Article II with respect to the Registrable
Securities Transferred to such Transferee Shareholder. If the Shareholder Transfers only a portion of its Registrable Securities, the
Shareholder shall retain all rights under this Agreement with respect to the portion of the Registrable Securities that it continues
to hold following such Transfer.

 

Article III

Right of first offer

 

Section 3.1     General.
From the date hereof until December 31, 2022, if the Company proposes to offer or sell any New Securities, the Company shall first
offer such New Securities to the Shareholder in accordance with this Article III.

 

Section 3.2     Timing
and Procedure. If the Company proposes to offer or sell any New Securities, the Company shall send a written notice thereof (an “Offer
Notice”) to the Shareholder. The Offer Notice shall include:

 

(a)            the
principal terms of the proposed offer or sale, including (i) the number and kind of New Securities to be offered or sold, and (ii) the
price per security of the New Securities, and (iii) all of the other material terms and conditions of the proposed offer or sale;
and

 

(b)            an
offer by the Company to sell to the Shareholder such portion of the New Securities (which may be all such New Securities) as may be requested
by the Shareholder (the “Offered Securities”), at the same price and otherwise on the same terms and conditions specified
in the Offer Notice; provided that, if the sale of the Offered Securities to the Shareholder would require approval of the stockholders
of the Company pursuant to the rules of the Nasdaq (or the rules of the principal market on which the Common Stock is then
listed), such offer and any sale of the Offered Securities shall be conditioned on such stockholder approval being obtained (it being
agreed that the Company shall not offer to sell or sell New Securities to any Person if such stockholder approval is not obtained).

 

    19

     

    

 

Section 3.3     Exercise
of Rights.(a)     If
the Shareholder desires to accept the offer contained in the Offer Notice, it shall send an irrevocable commitment (each a “Purchase
Commitment”) to the Company within ten (10) Business Days after the date of delivery of the Offer Notice specifying the
amount or proportion of the Offered Securities which it desires to purchase (the “Subscribed New Securities”). If
the Shareholder does not send a Purchase Commitment in accordance with the foregoing sentence, or duly sends a Purchase Commitment but
does not elect to purchase all of the Offered Securities in such Purchase Commitment, the Shareholder shall be deemed to have irrevocably
waived its right under this Article III with respect to those Offered Securities that are not Subscribed New Securities (the
 “Unsubscribed New Securities”) and the Company shall, subject to the terms and conditions of Article IV,
thereafter be free to offer and sell the Unsubscribed New Securities to any Person or Persons within one hundred and twenty (120) days
following the date of the Offer Notice (the “Sale Deadline”) on terms no more favorable to such Person or Persons
than those set forth in the Offer Notice. If the Company has not completed the sale of the Unsubscribed New Securities in accordance
with the foregoing sentence, the Company shall provide a new Offer Notice to the Shareholder on the terms and provisions set forth in
Section 3.2.

 

Section 3.4     Closing
of a Sale Transaction.(a)     The
closing of a sale transaction with respect to any Subscribed New Securities pursuant to this Article III shall take place
within ninety (90) days following the delivery by the Shareholder of the applicable Purchase Commitment in accordance with Section 3.3.
At the closing of any such sale transaction, the Company shall deliver to the Shareholder the originals of notes, certificates or other
instruments evidencing the Subscribed New Securities, in each case, free and clear of any Encumbrances, with any transfer tax stamps
affixed (if applicable), against delivery by the Shareholder of the applicable consideration.

 

Section 3.5     Exclusions.
The preceding provisions of this Article III shall not apply to:

 

(a)            any
issuance of New Securities to officers, employees, directors, advisors or consultants of the Company or any of its Subsidiaries, in each
case, in connection with their compensation or employment as such;

 

(b)            any
issuance of New Securities to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to an equipment
leasing or real property leasing transaction;

 

(c)            any
issuance of New Securities to suppliers or third-party service providers in connection with the provision of services;

 

(d)            any
issuance of New Securities pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all
of the assets or other reorganization or to a joint venture agreement;

 

    20

     

    

 

(e)            any
issuance of New Securities in connection with sponsored research, collaboration, technology license, development, marketing or similar
agreements or strategic partnerships;

 

(f)            any
issuance of shares of Common Stock pursuant to the exercise of stock options or warrants to purchase shares of Common Stock, or the vesting
of stock awards of Common Stock, in each case, that are issued and outstanding as of the date hereof; or

 

(g)            any
issuance of shares of Common Stock pursuant to the conversion of any convertible securities issued in accordance with the provisions
of this Article III.

 

Article IV

Preemptive Rights

 

Section 4.1     General.
From the date hereof until December 31, 2023, the Company shall not issue any New Securities to any Person, except (a) after
complying with the provisions of Article III, and (b) in compliance with the provisions of this Article IV.

 

Section 4.2     Timing
and Procedure. No less than twenty (20) Business Days prior to the consummation of the issuance of New Securities, the Company shall
send a written notice thereof (a “Participation Notice”) to the Shareholder. The Participation Notice shall include:

 

(a)            the
principal terms of the proposed issuance, including (i) the number and kind of New Securities to be included in the issuance, (ii) the
price per security of the New Securities, (iii) the percentage equal to (x) the aggregate number of Common Shares that are
Beneficially Owned (on a fully diluted as-converted basis) collectively by the Shareholder and any Affiliate Shareholders immediately
prior to the issuance of the New Securities divided by (y) the total number of issued and outstanding shares of Common Stock on
a fully diluted as-converted basis immediately prior to the issuance of the New Securities (the “Participation Percentage”),
and (iv) the name of each Person to whom the New Securities are proposed to be issued (each a “Prospective Subscriber”);
provided that, if the consideration to be paid by the Prospective Subscriber for the New Securities contains non-cash consideration,
then the Participation Notice shall also specify the fair market value (as reasonably determined by the Company Board) of such non-cash
consideration; and

 

(b)            an
offer by the Company to issue to the Shareholder such portion (not in any event to exceed the Participation Percentage) of the New Securities
to be included in the issuance as may be requested by the Shareholder (the “Preemptive Rights Securities”), at the
same price and otherwise on the same terms and conditions as the issuance to each of the Prospective Subscribers; provided that,
if consideration to be paid by the Prospective Subscriber for the New Securities contains non-cash consideration, then such offer shall
give the Shareholder the option to pay, in lieu of delivery of such non-cash consideration, cash in the amount of the fair market value
(as reasonably determined by the Company Board) of such non-cash consideration; and provided, further, that, if the issuance
of the Preemptive Rights Securities to the Shareholder would require approval of the stockholders of the Company pursuant to the rules of
Nasdaq (or the rules of the principal market on which the Common Stock is then listed), such offer and any issuance of the Preemptive
Rights Securities shall be conditioned on such stockholder approval being obtained (it being agreed that the Company shall not issue
New Securities to any Person if such stockholder approval is not obtained).

 

    21

     

    

 

Section 4.3     Exercise
of Rights.(a)     If
the Shareholder desires to accept the offer contained in the Participation Notice, it shall send an irrevocable commitment to the Company
within ten (10) Business Days after the date of delivery of the Participation Notice specifying the amount or proportion of the
Preemptive Rights Securities (not in any event to exceed the Participation Percentage) which it desires to be issued. If the Shareholder
has not so accepted such offer pursuant to the foregoing sentence, it shall be deemed to have irrevocably waived its right under this
Article IV and the Company shall thereafter be free to issue the New Securities to the Prospective Subscribers no later than
the Sale Deadline on terms no more favorable to the Prospective Subscribers than those set forth in the Participation Notice. If the
Company has not completed the sale of the New Securities in accordance with the foregoing sentence, the last sentence of Section 3.3
shall apply.

 

Section 4.4     Closing
of Preemptive Issuance.(a)     The
closing of an issuance pursuant to this Article IV shall take place at such time and place as the Company shall specify by
notice to the Shareholder given not less than three (3) Business Days prior to the closing of the issuance. At the closing
of any issuance under this Article IV, the Company shall deliver to the Shareholder the originals of notes, certificates
or other instruments evidencing the New Securities issued to the Shareholder, in each case, free and clear of any Encumbrances, with
any transfer tax stamps affixed (if applicable), against delivery by the Shareholder of the applicable consideration.

 

Section 4.5     Exclusions.
The preceding provisions of this Article IV shall not apply to:

 

(a)            any
sale or issuance of Subscribed New Securities to the Shareholder in accordance with Article III;

 

(b)            any
issuance of New Securities to officers, employees, directors, advisors or consultants of the Company or any of its Subsidiaries, in each
case, in connection with their compensation or employment as such;

 

(c)            any
issuance of New Securities to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to an equipment
leasing or real property leasing transaction;

 

(d)            any
issuance of New Securities to suppliers or third-party service providers in connection with the provision of services;

 

(e)            any
issuance of New Securities pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all
of the assets or other reorganization or to a joint venture agreement;

 

(f)            any
issuance of New Securities in connection with sponsored research, collaboration, technology license, development, marketing or similar
agreements or strategic partnerships;

 

    22

     

    

 

(g)            any
issuance of shares of Common Stock pursuant to the exercise of stock options or warrants to purchase shares of Common Stock, or the vesting
of stock awards of Common Stock, in each case, that are issued and outstanding as of the date hereof; or

 

(h)            any
issuance of shares of Common Stock pursuant to the conversion of any convertible securities issued in accordance with the provisions
of this Article IV.

 

Article V

BOARD OF DIRECTORS

 

Section 5.1     Initial
Shareholder Designees. The Company has elected the following Persons to serve as Directors in the class of Directors and the committees
of the Company Board, in each case, as identified below:

 

	Name
    of Director	Class of
    Directors to Serve in	Board
    Committee(s) to serve in
	Faisal
    G. Sukhtian 	Class I	Nominating
    and Corporate Governance Committee, Executive Committee
	Yezan
    Haddadin	Class I	Audit
    Committee, Compensation Committee and Executive Committee 

 

Section 5.2     Right
of Shareholder to Nominate Directors. So long as the Shareholder and any Affiliate Shareholders Beneficially Own, in the aggregate,
at least five percent (5%) of the Company’s outstanding Common Stock on a fully diluted as-converted basis, the Shareholder shall
have the right, subject to compliance with the applicable rules of Nasdaq, to nominate to the Company Board a number of Directors
(each, a “Shareholder Nominee” and, after being elected to the Company Board, a “Shareholder Director”)
equal to the total number of Directors constituting the Company Board multiplied by the percentage of the outstanding shares of Common
Stock that are Beneficially Owned (on a fully diluted as-converted basis) by the Shareholder and any Affiliate Shareholders, BioLexis
and its Affiliates (including, any Affiliate of Tenshi Life Sciences Private Limited) (such shareholders, collectively, the “Ownership
Group”), rounding up in the case of any resulting fractional number of Directors, less the number of Shareholder Nominees who
are members of the Company Board and not subject to election at such Election Meeting; provided that any such resulting
fractional number of Directors shall be rounded down in the event that rounding up would result in the number of Shareholder Nominees
constituting a majority of the Directors while the Ownership Group holds less than fifty percent (50%) of the outstanding shares of Common
Stock (on a fully diluted as-converted basis); provided, further, that, if the total number of Directors constituting
the Company Board is seven (7), while the Ownership Group Beneficially Own, in the aggregate, greater than or equal to fifty percent
(50%) of the outstanding shares of Common Stock (on a fully diluted as-converted basis) and less than or equal to fifty-seven percent
(57%) of the outstanding shares of Common Stock (on a fully diluted as-converted basis), the Shareholder shall have the right to nominate
four (4) Directors to the Company Board. The Shareholder shall have the right to nominate the Shareholder Nominees from its Affiliates.
Any resignation of a Shareholder Director required to give effect to this Section 5.2 as a result of a reduction
in the amount of outstanding shares of Common Stock Beneficially Owned (on a fully diluted as-converted basis) by the Ownership Group
will comply with the applicable rules of Nasdaq; provided that, for the avoidance of doubt, any such resignation need not be effective
until the next annual meeting of the stockholders of the Company.

 

    23

     

    

 

Section 5.3     Election
of Shareholder Directors to the Board. Following the date hereof, to the extent that a Shareholder Nominee must stand for election
or a Shareholder Director must stand for reelection, as the case may be, to the Company Board in connection with any annual or special
meeting of stockholders of the Company at which Directors are to be elected (each such annual or special meeting, an “Election
Meeting”), subject to the first sentence of Section 5.5(a), the Company agrees to (a) nominate and recommend
that the holders of Capital Stock who are entitled to vote at such Election Meeting vote in favor of the election of such Shareholder
Nominees or the reelection of such Shareholder Directors, as the case may be, (b) support the Shareholder Nominees for election
or the Shareholder Directors for reelection, as the case may be, in a manner no less rigorous and favorable than the manner in which
the Company supports its other nominees and (c) otherwise use its reasonable best efforts to cause the election of the Shareholder
Nominees or the reelection of the Shareholder Directors, as the case may be, to the Company Board at each Election Meeting.

 

Section 5.4     Proxy
or Information Statement. Within a reasonable time prior to the filing with the SEC of the Company’s proxy statement or information
statement with respect to any Election Meeting, the Company shall, to the extent the Shareholder is then entitled to representation on
the Company Board in accordance with this Agreement, provide the Shareholder with the opportunity to review and comment on the information
contained in such proxy or information statement applicable to Shareholder Nominees or Shareholder Directors and shall take into account
all reasonable comments from the Shareholder.

 

Section 5.5     Qualification
and Replacements of Shareholder Directors.

 

(a)            Each
Shareholder Director shall at all times until cessation of service on the Company Board meet any (i) applicable requirements or
qualifications under applicable Law or applicable stock exchange rules and (ii) the Company’s standard qualifications
for Directors. Notwithstanding anything set forth to the contrary in the Charter or the Bylaws, (A) if a Shareholder Director is
unable or unwilling to serve as a Director for any reason, (B) if a Shareholder Director is removed (upon death, resignation or
otherwise), or (C) in the event that a Shareholder Director or a Shareholder Nominee, as the case may be, fails to be reelected
or elected, as the case may be, at an Election Meeting solely as a result of failing to receive the required vote of the holders of voting
Capital Stock as required by the Charter and the Bylaws, in each case of clauses (A), (B) and (C), the Shareholder shall have the
exclusive right to submit the name of a replacement candidate for such Shareholder Director or Shareholder Nominee, as the case may be
(a “Replacement”), to the Governance Committee of the Company for its approval. If so approved, such Replacement shall
serve as the Shareholder Nominee for election in the same class of Directors on the Company Board as the Shareholder Director or Shareholder
Nominee for which such Person serves as a Replacement. For each proposed Replacement that is not approved by the Company, the Shareholder
shall have the right to submit another proposed Replacement to the Governance Committee for its approval on the same basis as set forth
in the immediately preceding sentence and, for the avoidance of doubt, the Company shall not fill the vacancy on the Company Board during
any period in which the appointment of a Shareholder Director is pending without the prior written consent of the Shareholder. The Shareholder
shall have the right to continue submitting the name of a proposed Replacement to the Governance Committee for its approval until the
Governance Committee approves that a Replacement may serve as a nominee for election or appointment as a Director or to serve as a Director,
whereupon such Person shall be appointed as the Replacement. To the extent a Replacement is nominated pursuant to this Section 5.5(a),
the Company’s obligations under Section 5.3 shall be fulfilled with respect to such Replacement.

 

    24

     

    

 

(b)            If
any Shareholder Director is serving on the Company Board on the Expiration Date, the Shareholder shall use its commercially reasonably
efforts to cause such Shareholder Director to promptly tender his or her resignation to the Company Board, which resignation the Governance
Committee shall determine to accept or reject in its sole discretion.

 

Section 5.6     Board
Committee Representation. So long as the Shareholder has the right to nominate Directors to the Company Board in accordance with
the terms of this Agreement, the Shareholder shall have the right to require that at least one Shareholder Director be appointed to each
of the committees of the Company Board, subject to applicable requirements or qualifications under applicable Law or applicable stock
exchange rules (including with respect to director independence).

 

Section 5.7     Rights
of the Shareholder Directors.

 

(a)            The
Company shall notify each Shareholder Director, at the same time and in the same manner as such notification is delivered to the other
members of the Company Board, of all regular meetings and special meetings of the Company Board and of all regular and special meetings
of any committee of the Company Board of which such Shareholder Director is a member. The Company and the Company Board shall provide
each Shareholder Director with copies of all notices, minutes, consents and other material that it provides to all other members of the
Company Board concurrently as such materials are provided to the other members.

 

(b)            Each
Shareholder Director shall be entitled to the same directors’ and officers’ insurance coverage as the other Directors and
the same indemnification from the Company as such other Directors, in each case, effective no later than the date on which such Shareholder
Director joins the Company Board. If the Company enters into indemnification agreements with its Directors generally, the Company will
enter into an indemnification agreement with each Shareholder Director in the same form and substance as the other Directors.

 

Section 5.8     No
Duty for Corporate Opportunities(a)     .
Notwithstanding anything to the contrary in this Agreement or in any policy or code of the Company, the Company, on behalf of itself
and its Subsidiaries, (a) acknowledges and affirms that the Shareholder and its Affiliates, employees, directors, partners and members,
including any Shareholder Director (the “Shareholder Group”), (i) have participated (directly or indirectly)
and will continue to participate (directly or indirectly) in private equity, venture capital and other direct investments in corporations,
joint ventures, limited liability companies and other entities (“Other Investments”), including Other Investments
engaged in various aspects of businesses similar to those engaged in by the Company and its Subsidiaries that may, are or will be competitive
with the Company’s or any of its Subsidiaries’ businesses or that could be suitable for the Company’s or any of its
Subsidiaries’ interests, (ii) have interests in, participate with, aid and maintain seats on the board of directors or similar
governing bodies of, Other Investments, (iii) may develop or become aware of business opportunities for Other Investments, and (iv) may
or will, as a result of matters referred to in this Agreement, the nature of the Shareholder Group’s businesses and other factors,
have conflicts of interest or potential conflicts of interest, (b) hereby renounces and disclaims any interest or expectancy in
any business opportunity (including any Other Investments) or any other opportunities, in each case, that may arise in connection with
the circumstances described in the foregoing clauses (i)-(iv) (collectively, the “Renounced Business Opportunities”),
(c) acknowledges and affirms that no member of the Shareholder Group shall have any obligation to communicate or offer any Renounced
Business Opportunity to the Company or any of its subsidiaries, and any member of the Shareholder Group may pursue a Renounced Business
Opportunity, and (d) acknowledges and affirms that any of the activities set forth in this Section 5.8 shall not be
considered a violation of any policies and codes of the Company.  Notwithstanding the foregoing, the Company does not renounce its
interest in any corporate opportunity if such corporate opportunity was offered to a Shareholder Director solely in his or her capacity
as a Director; provided, that such opportunity has not been separately presented to the Shareholder or its Affiliates or is not
otherwise being independently pursued by the Shareholder or its Affiliates (in each case whether before or after such opportunity is
presented to such Director).

 

    25

     

    

 

Article VI

CERTAIN OTHER AGREEMENTS

 

Section 6.1     Additional
Covenants. Certificates in book-entry form evidencing the Common Shares shall not contain any legend (including the legend set forth
in Section 1.2(a)): (i) while a registration statement covering the resale of such security is effective under the Securities
Act, (ii) following any sale of such Common Shares pursuant to Rule 144, (iii) if such Common Shares are eligible for
sale under Rule 144; provided that the Company shall be in compliance with the current public information required under
Rule 144, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations
and pronouncements issued by the staff of the Commission) (the earliest such date, the “Legend Removal Date”). The
Company shall cause its counsel to issue a legal opinion to the transfer agent of the Company (“Transfer Agent”) or
the Shareholder promptly after the Legend Removal Date if required by the Transfer Agent to effect the removal of the legend hereunder,
or if requested by Shareholder, respectively. The Company agrees that following the Legend Removal Date it will, no later than the Standard
Settlement Period Delivery Date (as defined below) following the delivery by the Shareholder to the Company or the Transfer Agent of
a certificate in book-entry form representing Common Shares issued with a restrictive legend deliver or cause to be delivered to the
Shareholder a certificate in book-entry form representing such shares that is free from all restrictive and other legends. The Company
may not make any notation on its records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth
in this Section 6.1. Certificates in book-entry form for Common Shares subject to legend removal hereunder shall be transmitted
by the Transfer Agent to the Shareholder as directed by the Shareholder. As used herein, “Standard Settlement Period”
means the standard settlement period, expressed in a number of trading days, on the Company’s primary trading market with respect
to the Common Stock as in effect on the date of delivery of a certificate in book-entry form representing Common Shares, issued with
a restrictive legend and “Standard Settlement Period Delivery Date” means the trading day for delivery in compliance
with the Standard Settlement Period.

 

    26

     

    

 

Article VII

TERMINATION

 

Section 7.1     Termination.
This Agreement, other than Article II, shall terminate upon the earlier of (a) the date that is three (3) months
following the Expiration Date and (b) the mutual written agreement of the Shareholder and the Company. The provisions of Article II
shall terminate upon the earlier of (i) the time when there are no longer any Registrable Securities and (ii) the mutual
written agreement of the Shareholder and the Company.

 

Section 7.2     Effect
of Termination; Survival. In the event of any termination of this Agreement pursuant to the first sentence of Section 7.1,
this Agreement shall be terminated, and there shall be no further liability or obligation hereunder on the part of any Party, other than
this Section 7.2 and Article VIII, which provisions shall survive such termination; provided, however,
that nothing contained in this Agreement (including this Section 7.2) shall relieve a Party from liability for any breach
of any of its representations, warranties, covenants or agreements set forth in this Agreement to the extent occurring prior to such
termination.

 

Article VIII

GENERAL PROVISIONS

 

Section 8.1     Confidential
Information. The Shareholder shall hold in confidence, and shall not disclose to any Person, unless and to the extent disclosure
is required by judicial or administrative process or by other requirement of Law or the applicable requirements of any regulatory agency
or relevant stock exchange, all non-public records, books, Contracts, instruments, computer data and other data and information (collectively,
 “Confidential Information”) concerning the Company and its Subsidiaries furnished to it by Company or its Representatives
pursuant to this Agreement (except (a) to the extent such Confidential Information can be shown to have been (i) previously
known by the Shareholder or any Affiliate Shareholder on a non-confidential basis, (ii) in the public domain through no breach of
the Shareholder of any of the confidentiality obligations to the Company, (iii) later acquired by the Shareholder or any Affiliate
Shareholder from other sources not known by the Shareholder or such Affiliate Shareholder to be subject to a duty of confidentiality
with respect to such Confidential Information, and (b) Confidential Information may be disclosed by the Shareholder to any Affiliate
Shareholder or the Shareholder’s or any Affiliate Shareholder’s respective Representatives in connection with (i) the
management of the investment of the Shareholder and the Affiliate Shareholders in the Company or (ii) any offerings under Article II;
provided that the Shareholder informs any such Person that such information is confidential. If disclosure is required by judicial
or administrative process or by any other requirement of Law, the Shareholder shall provide the Company with prompt written notice to
the extent permissible by Law, together with a copy of any material proposed to be disclosed, so that the Company may (a) seek,
at the Company’s expense, an appropriate protective order or other appropriate relief (and the Shareholder and the Affiliate Shareholders
shall reasonably cooperate with the Company, at the Company’s expense, to obtain such order or relief), or (b) if the Company
so elects, waive compliance with the provisions of this Section 8.1.

 

    27

     

    

 

Section 8.2     Fees
and Expenses. All costs and expenses incurred by the Parties in connection with the negotiation, execution and delivery of this Agreement
and any amendments relating thereto, and any costs and expenses, including advisor and attorney fees, incurred by the Shareholder or
an Affiliate Shareholder in connection with its ownership of any securities of the Company, including the Common Shares, will be borne
solely and entirely by the Party incurring such expense.

 

Section 8.3     Notices.
All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be given or made (and
shall be deemed to have been duly given or made upon receipt) by delivery in person, by an internationally recognized overnight courier
service, or by email transmission (upon confirmation of receipt and with a confirmatory copy sent by an internationally recognized overnight
courier service) to the respective parties hereto at the following addresses (or at such other address for a party as shall be specified
in a notice given in accordance with this Section 8.3):

 

If to the Company, addressed
to it at:

 

Outlook Therapeutics, Inc.

485 Route 1 South

Building F, Suite 320

Iselin, New Jersey 08852

Email: LawrenceKenyon@OutlookTherapeutics.com

Attention: Lawrence A. Kenyon

 

With a copy (which
shall not constitute notice) to:

 

Cooley LLP

55 Hudson Yards

New York, New York 10001

Email: ypierre@cooley.com

Attention: Yvan-Claude Pierre

 

If to the Shareholder, addressed
to it at:

 

GMS Ventures and Investments

c/o Intertrust Corporate Services (Cayman)
Limited

190 Elgin Avenue

George Town

Grand Cayman KY1-9007

Cayman Islands

Email: info@gmsholdings.com

 

With a copy (which
shall not constitute notice) to:

 

Shearman &
Sterling LLP

300 W. 6th Street, Suite 2250

Austin, Texas 78701

Email: rdenton@shearman.com

Attention: J. Russel Denton

 

    28

     

    

 

Section 8.4     Definitions.
For purposes of this Agreement, the following terms have the meanings indicated:

 

“Action”
means any litigation, suit, claim, action, proceeding, arbitration, mediation, hearing, inquiry or investigation (in each case, whether
civil, criminal or investigative).

 

“Affiliate”
of a specified Person means a Person who, directly or indirectly through one or more intermediaries, controls, is controlled by, or is
under common control with, such specified Person; provided that no portfolio company of the Shareholder, GMS Pharma (Singapore)
Pte. Limited (or its Affiliates), Tenshi Life Sciences Pte. Limited (or its Affiliates) or Tenshi Life Sciences Private Limited (or its
Affiliates) shall be deemed to be an “Affiliate”.

 

“Affiliate Shareholder”
means any of: (a) the transferee of an Affiliate Transfer pursuant to Section 1.1(b), (b) the Shareholder, or (c) GMS
Holdings, LLC (or its Affiliates).

 

“Affiliate Transfer”
has meaning set forth in Section 1.1(b).

 

“Agreement”
has the meaning set forth in the preamble to this Agreement.

 

“ASR Eligible”
means the Company meets or is deemed to meet the eligibility requirements to file an ASRS as set forth in General Instruction I.D. to
Form S-3.

 

“ASRS”
means an “automatic shelf registration statement” as defined in Rule 405 promulgated under the Securities Act.

 

“Beneficial Ownership”
and related terms such as “Beneficially Owned” or “Beneficial Owner” have the meaning given such terms in Rule 13d-3
under the Exchange Act and a Person’s Beneficial Ownership of Capital Stock shall be calculated in accordance with the provisions
of such Rule.

 

“Business Day”
means any day other than a Saturday, Sunday or other day on which commercial banks in New York, New York, or Singapore, Republic of Singapore
are authorized or required by Law to remain closed.

 

“Bylaws”
means the Amended and Restated Bylaws of the Company, as may be amended from time to time.

 

“Capital Stock”
means any and all shares of common stock, preferred stock or other forms of equity authorized and issued by the Company (however designated,
whether voting or non-voting) and any instruments convertible into or exercisable or exchangeable for any of the foregoing (including
any options or swaps).

 

    29

     

    

 

“Charter”
means the Company’s Amended and Restated Certificate of Incorporation, as may be amended from time to time.

 

“Common Shares”
means shares of Common Stock, other Capital Stock, or any options, warrants or other securities convertible or exchangeable for Common
Stock or Capital Stock held by the Shareholder, any Affiliate Shareholder and any Transferee Shareholder at any time following the date
of this Agreement.

 

“Common Stock”
means the common stock, par value $0.01 per share, of the Company.

 

“Company”
has the meaning set forth in the preamble to this Agreement.

 

“Company Board”
means the Board of Directors of the Company.

 

“Company Registration
Rights Indemnitee” has the meaning set forth in Section 2.8(a)(ii).

 

“Confidential Information”
has the meaning set forth in Section 8.1.

 

“Contract”
means any oral or written binding contract, subcontract, agreement, note, bond, mortgage, indenture, lease, sublease, license, sublicense,
permit, franchise or other instrument, obligation, commitment or arrangement or understanding of any kind or character.

 

“control”
(including the terms “controlled by” and “under common control with”) means the possession, directly
or indirectly, or as trustee or executor, of the power to direct or cause the direction of the management and policies of a Person, whether
through the ownership of voting securities, as trustee or executor, by Contract or credit arrangement or otherwise.

 

“controlling person”
has the meaning set forth in Section 2.8(a)(i).

 

“Damages”
means any and all claims, demands, suits, actions, causes of actions, losses, costs, damages, liabilities, judgments, and reasonable
and documented out-of-pocket expenses incurred or paid, including reasonable attorneys’ fees, costs of investigation or settlement,
other professionals’ and experts’ fees, court or arbitration costs, but specifically excluding consequential damages, lost
profits and indirect damages and punitive damages, exemplary damages and any taxes incurred as a result of any recovery received.

 

“Demand Registration”
has the meaning set forth in Section 2.1(a).

 

“Demand Registration
Request” has the meaning set forth in Section 2.1(a).

 

“Director”
means a director of the Company.

 

“Disclosure Package”
means, with respect to any offering of Registrable Securities, (a) the preliminary Prospectus, (b) each Free Writing Prospectus,
and (c) all other information, in each case, that is deemed, under Rule 159 under the Securities Act, to have been conveyed
to purchasers of Registrable Securities at the time of sale of such securities.

 

“Effectiveness Period”
has the meaning set forth in Section 2.7.

 

    30

     

    

 

“Election Meeting”
has the meaning set forth in Section 5.3.

 

“Encumbrances”
means mortgages, pledges, liens, security interests, conditional and installment sale agreements, encumbrances, charges or other claims
of third parties or restrictions of any kind, including any easement, reversion interest, right of way or other encumbrance to title,
limitations on voting rights, or any option, right of first refusal or right of first offer.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, as in effect from time
to time.

 

“Expiration Date”
means the date at which the Shareholder and any Affiliate Shareholders cease to Beneficially Own, in the aggregate, at least five (5.0%)
of the outstanding shares of Common Stock on a fully diluted as-converted basis.

 

“FINRA”
means the Financial Industry Regulatory Authority, Inc. or any successor regulatory organization.

 

“Free Writing Prospectus”
means any “free writing prospectus” as defined in Rule 405 promulgated under the Securities Act relating to the Registrable
Securities included in the applicable Registration Statement that has been approved for use by the Company.

 

“GAAP”
means United States generally accepted accounting principles.

 

“Governance Committee”
means the Nominating and Corporate Governance Committee of the Company.

 

“Governmental Entity”
means any federal, national, foreign, supranational, state, provincial, county, local or other government, governmental, regulatory or
administrative authority, agency, instrumentality or commission or any court, tribunal, or judicial or arbitral body of competent jurisdiction.

 

“Indebtedness”
means, with respect to any Person, without duplication: (a) all indebtedness of such Person, whether or not contingent, for borrowed
money, including all obligations of such Person evidenced by notes, bonds, debentures or other similar instruments, (b) all obligations
of such Person for the deferred purchase of property or services, (c) all indebtedness created or arising under any conditional
sale or other title retention agreement with respect to property acquired by such Person (even if the rights and remedies of the seller
or lender under such agreement in the event of default are limited to repossession or sale of such property), (d) all obligations
of such Person as lessee under Leases (as defined in the Purchase Agreement) that have been or should be, in accordance with GAAP, recorded
as capital leases, (e) all obligations, contingent or otherwise, of such Person under acceptance, letter of credit or similar facilities,
(f) all liabilities or obligations with respect to interest rate swaps, caps, collars and similar hedging obligations, (g) all
Indebtedness of others referred to in clauses (a) through (f) above guaranteed (or in effect guaranteed) directly or indirectly
in any manner by such Person, and (h) all Indebtedness of others referred to in clauses (a) through (g) above secured
by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Encumbrance on
property (including accounts and Contract rights) owned by such Person, even though such Person has not assumed or become liable for
the payment of such Indebtedness.

 

    31

     

    

 

“issuer free writing
prospectus” has the meaning set forth in Section 2.9.

 

“Law”
any U.S. or non-U.S. federal, state, local, national, supranational, foreign or administrative law (including common law), statute, ordinance,
regulation, requirement, regulatory interpretation, rule, code or Order.

 

“Legend Removal
Date” has the meaning set forth in Section 6.1.

 

“Nasdaq”
has the meaning set forth in Section 2.6(h).

 

“New Securities”
means, collectively, (a) any shares of Common Stock, (b) any shares of Capital Stock, (c) any class or series of shares
(including a new class of common shares of the Company other than shares of Common Stock), any preference shares or any other equity-like
or hybrid securities (including debt securities with equity components), including options, warrants, convertibles, exchangeable or exercisable
securities, share appreciation rights or any other security or arrangement whose economic value is derived from the value of the equity
of the Company and its Subsidiaries, and (d) any debt securities of the Company, including notes, bonds, debentures or other similar
instruments, in each case of clauses (a), (b), (c) and (d), issued by the Company after the date hereof,.

 

“Notice of Reg Rights
Claim” has the meaning set forth in Section 2.8(b)(i).

 

“Notice of Suspension”
has the meaning set forth in Section 2.4(a).

 

“Offered Securities”
has the meaning set forth in Section 3.2(b).

 

“Offer Notice”
has the meaning set forth in Section 3.2.

 

“Order”
means any order (temporary or otherwise), judgment, injunction, award, decision, determination, stipulation, ruling, subpoena, writ,
decree or verdict entered by or with any Governmental Entity.

 

“Other Investments”
has meaning set forth in Section 5.8.

 

“Participation Notice”
has the meaning set forth in Section 4.2.

 

“Participation Percentage”
has the meaning set forth in Section 4.2(a).

 

“Party”
and “Parties” have the meanings set forth in the preamble to this Agreement.

 

“Person”
means an individual, company, corporation, partnership, limited partnership, limited liability company, syndicate, person (including
a “person” as defined in Section 13(d)(3) of the Exchange Act), trust, association or entity or government, political
subdivision, agency or instrumentality of a government.

 

“Preemptive Rights
Securities” has the meaning set forth in Section 4.2(b).

 

“Primary Registration
Statement” has the meaning set forth in Section 2.2.

 

    32

     

    

 

“Prospective Subscriber”
has the meaning set forth in Section 4.2(a).

 

“Prospectus”
means the prospectus included in a Registration Statement, as amended or supplemented by any prospectus supplement and by all other amendments
thereto, including post-effective amendments, and all material incorporated by reference, or deemed to be incorporated by reference,
into such prospectus.

 

“Public Offering”
means an underwritten public offering of Common Stock pursuant to an effective registration statement under the Securities Act, other
than (i) pursuant to a registration statement on Form S-4 or Form S-8 or any similar or successor form under the Securities
Act or (ii) in connection with an offering of subscription rights.

 

“Purchase Agreement”
means the Purchase Agreement, dated as of September 7, 2017, by and among the Company and BioLexis.

 

“Purchase Commitment”
has the meaning set forth in Section 3.3.

 

“Reg Rights Claim”
has the meaning set forth in Section 2.8(b)(i).

 

“Reg Rights Indemnified
Person” has the meaning set forth in Section 2.8(b)(i).

 

“Reg Rights Indemnifying
Person” has the meaning set forth in Section 2.8(b)(i).

 

“Registrable
Securities” means the Common Shares held by the Shareholder, any Affiliate Shareholder and any Transferee Shareholder
at any time following the date of this Agreement; provided, that any such Common Shares will cease to be Registrable Securities
when (a) they are sold pursuant to a Registration Statement, (b) they are sold pursuant to Rule 144 (or any similar provisions
then in force), or (c) they are sold in a single transaction or series of transactions without volume, manner of sale or other limitations
under Rule 144 (or any similar provisions then in force).

 

“Registration Expenses”
means (whether or not any Registration Statement is declared effective or any of the transactions described herein is consummated) all
expenses incurred by the Company in filing a Registration Statement, including, all registration and filing fees, fees and disbursements
of counsel for the Company, SEC or FINRA registration and filing fees, all applicable ratings agency fees, expenses of the Company’s
independent accountants in connection with any regular or special reviews or audits incident to or required by any such registration,
fees and expenses of compliance with securities or “blue sky” Laws, costs of any comfort letters required by any underwriter,
listing fees, printing, transfer agent’s and registrar’s fees, cost of distributing Prospectuses in preliminary and final
form as well as any supplements thereto, the Company’s internal expenses, the expense of any annual audit or quarterly review,
the expenses and fees for listing the securities to be registered on Nasdaq or any other securities exchange, roadshow expenses, all
other expenses incident to the registration of the Registrable Securities and all reasonable fees and disbursements of one counsel to
the Shareholder selected by the Shareholder; provided, that the term “Registration Expenses” does not include, and
the Company shall not be responsible for, Selling Expenses.

 

    33

     

    

 

“Registration Statement”
means a registration statement of the Company on an appropriate form under the Securities Act filed with the SEC covering the resale
of Registrable Securities, including the Prospectus, amendments and supplements to such Registration Statement, including post-effective
amendments, all exhibits and all materials incorporated by reference or deemed to be incorporated by reference in such Registration Statement.

 

“Renounced Business
Opportunities” has meaning set forth in Section 5.8.

 

“Replacement”
has the meaning set forth in Section 5.5(a). At such time as a Replacement is elected, under the terms of this Agreement,
to serve as a Director, such Replacement shall be deemed a Shareholder Director for purposes of this Agreement.

 

“Representatives”
means a Person’s officers, directors, employees, accountants, consultants, legal counsel, investment bankers, other advisors, authorized
agents and other representatives.

 

“Requesting Third
Party Shareholders” has the meaning set forth Section 2.2(b).

 

“Restricted Stock”
has the meaning set forth Section 2.5.

 

“Rule 144”
means Rule 144 under the Securities Act or any replacement or successor rule promulgated under the Securities Act.

 

“Sale Deadline”
has the meaning set forth in Section 3.3.

 

“SEC”
means the United States Securities and Exchange Commission.

 

“Secondary Registration
Statement” has the meaning set forth Section 2.2(b).

 

“Securities Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, as in effect from time to time.

 

“Selling
Expenses” means, in connection with the registration or offering and sale of the Registrable Securities, (a) all
underwriting fees, discount and selling commissions fees, (b) stock transfer taxes applicable to the sale of the Registrable Securities,
and (c) fees and expenses of any counsel to the Shareholder other than the counsel referred to in the definition of Registration
Expenses.

 

“settlement”
and “settle” have the meanings set forth in Section 2.8(c)(iv).

 

“Shareholder”
has the meaning set forth in the preamble to this Agreement.

 

“Shareholder Director”
has meaning set forth in Section 5.2.

 

“Shareholder Group”
has meaning set forth in Section 5.8.

 

“Shareholder Nominee”
has meaning set forth in Section 5.2.

 

    34

     

    

 

“Shareholder Registration
Rights Indemnitee” has the meaning set forth in Section 2.8(a)(i).

 

“Shelf Registration
Statement” means a registration statement filed with the SEC for the sale of Common Shares pursuant to Rule 415 under
the Securities Act.

 

“Standard Settlement
Period” has the meaning set forth in Section 6.1.

 

“Standard Settlement
Period Delivery Date” has the meaning set forth in Section 6.1.

 

“Subscribed New
Securities” has the meaning set forth in Section 3.3.

 

“Subsidiary”
of any specified Person means an Affiliate controlled by such Person, directly or indirectly, through one or more intermediaries.

 

“Suspension Period”
has the meaning set forth in Section 2.4(a).

 

“Third-Party Reg
Rights Claim” has the meaning set forth in Section 2.8(b)(ii).

 

“Transfer”
means to, directly or indirectly, sell, transfer, assign, pledge, encumber, hypothecate or similarly dispose of, either voluntarily or
involuntarily, or to enter into any Contract, option or other arrangement or understanding with respect to the sale, transfer, assignment,
pledge, encumbrance, hypothecation or similar disposition of, any securities.

 

“Transfer Agent”
has the meaning set forth in Section 6.1.

 

“Transferee Shareholder”
shall have the meaning set forth in Section 2.14.

 

“Underwriter Cutback”
shall have the meaning set forth in Section 2.1(e).

 

“Underwritten Block
Trade” shall have the meaning set forth in Section 2.1(f).

 

“Unsubscribed New
Securities” has the meaning set forth in Section 3.3.

 

Section 8.5     Interpretation;
Headings. When a reference is made in this Agreement to an Exhibit, a Schedule or a Section, such reference shall be to an Exhibit,
a Schedule or a Section of this Agreement unless otherwise indicated. The table of contents, index of defined terms and headings
contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.
Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be
deemed to be followed by the words “without limitation.” The words “hereof”, “hereto”, “hereby”,
 “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement
as a whole and not to any particular provision of this Agreement. The term “or” is not exclusive. The word “extent”
in the phrase “to the extent” shall mean the degree to which a subject or other thing extends, and such phrase shall not
mean simply “if”. The definitions contained in this Agreement are applicable to the singular as well as the plural forms
of such terms. Any agreement, instrument or Law defined or referred to herein means such agreement, instrument or Law as from time to
time amended, modified or supplemented, unless otherwise specifically indicated. References to a Person are also to its successors and
permitted assigns. When calculating the period of time before which, within which or following which any act is to be done or step taken
pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded, and if the last day of
such period is not a Business Day, the period shall end on the immediately following Business Day. Unless otherwise specifically indicated,
all references to “dollars” and “$” will be deemed references to the lawful money of the United States of America.
Each of the parties hereto has participated in the drafting and negotiation of this Agreement. If an ambiguity or question of intent
or interpretation arises, this Agreement must be construed as if it is drafted by all the parties hereto, and no presumption or burden
of proof shall arise favoring or disfavoring any party by virtue of authorship of any of the provisions of this Agreement. References
to “days” shall mean “calendar days” unless expressly stated otherwise. No specific provision, representation
or warranty shall limit the applicability of a more general provision, representation or warranty. It is the intent of the parties hereto
that each representation, warranty, covenant, condition and agreement contained in this Agreement shall be given full, separate, and
independent effect and that such provisions are cumulative. Any reference in this Agreement to a date or time shall be deemed to be such
date or time in the City of New York, New York, U.S.A., unless otherwise specified.

 

    35

     

    

 

Section 8.6     Severability.
If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of Law, or public
policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties hereto as closely as possible in a mutually acceptable manner
in order that such transactions be consummated as originally contemplated to the fullest extent possible.

 

Section 8.7     Entire
Agreement; Amendments. This Agreement (including the schedules and exhibits hereto) constitutes the entire agreement among the parties
with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, among the parties,
or any of them, with respect to the subject matter hereof. This Agreement may not be amended except by an instrument in writing signed
on behalf of each of the parties hereto.

 

Section 8.8     Assignment;
No Third Party Beneficiaries. Except as expressly provided herein, neither this Agreement nor any of the rights, interests or obligations
hereunder shall be assigned by any party hereto, in whole or in part (whether pursuant to a merger, by operation of law or otherwise),
without the prior written consent of the other party hereto. Subject to the immediately preceding sentence, this Agreement shall be binding
upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and permitted assigns, and nothing
in this Agreement, express or implied, is intended to or shall confer upon any other Person any right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement.

 

Section 8.9     Further
Assurances. Each Party shall cooperate, take such actions, enter into such agreements (including customary indemnification and contribution
agreements) and execute such documents as may be reasonably requested by any other Party in order to carry out the provisions and purposes
of this Agreement and the transactions contemplated hereby; provided, however, that no Party shall be obligated to take
any actions or omit to take any actions that would be inconsistent with applicable Law.

 

    36

     

    

 

Section 8.10   Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the laws
of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the laws of any jurisdiction other than the State of New
York. The parties hereto hereby irrevocably and unconditionally consent to submit to the exclusive jurisdiction of the courts of the
State of New York and the United States of America, in each case located in the County of New York, for any Action seeking to enforce
any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby
(whether brought by any party or any of its Affiliates or against any party or any of its Affiliates). Consistent with the preceding
sentence, each of the parties hereto hereby (a) submits to the exclusive jurisdiction of such courts for the purpose of any Action
arising out of or relating to this Agreement brought by either party hereto, (b) agrees that service of process will be validly
effected by sending notice in accordance with Section 8.3, (c) irrevocably waive, and agree not to assert by way of
motion, defense, or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that
the venue of the Action is improper, or that this Agreement or the transactions contemplated by this Agreement may not be enforced in
or by any of the above named courts, and (d) agrees not to move to transfer any such Action to a court other than any of the above-named
courts. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY. EACH OF THE PARTIES HERETO HEREBY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY
HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
WAIVER AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT,
AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.10.

 

Section 8.11   Counterparts.
This Agreement may be executed and delivered (including by facsimile transmission or other means of electronic transmission, such as
by electronic mail in “pdf” form) in counterparts, and by the different parties hereto in separate counterparts, each of
which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

 

Section 8.12   Specific
Performance. The parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Each party agrees that, in the
event of any breach or threatened breach by the other party of any covenant or obligation contained in this Agreement, the non-breaching
party shall be entitled (in addition to any other remedy that may be available to it whether in law or equity, including monetary damages)
to (a) an Order of specific performance to enforce the observance and performance of such covenant or obligation, and (b) an
injunction restraining such breach or threatened breach. Each party further agrees that neither the other party nor any other Person
shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy
referred to in this Section 8.12, and each party irrevocably waives any right it may have to require the obtaining, furnishing
or posting of any such bond or similar instrument.

 

    37

     

    

 

Section 8.13     Waiver.
Any party hereto entitled to the benefits thereof may, to the extent permitted by Law (a) extend the time for the performance of
any of the obligations or other acts of the other party hereto, (b) waive any inaccuracies in the representations and warranties
contained herein, and (c) waive compliance with any of the covenants, agreements or conditions contained herein. Any such extension
or waiver shall be valid only if set forth in an instrument in writing signed by the party or parties to be bound thereby. Notwithstanding
the foregoing, no failure or delay by a party hereto in exercising any right hereunder shall operate as a waiver thereof nor shall any
single or partial exercise thereof preclude any other or future exercise of any other right hereunder.

 

[Signature
Page Follows]

 

    38

     

    

 

IN WITNESS WHEREOF, the Parties
have caused this Agreement to be executed, as of the date first written above, by their respective officers thereunto duly authorized.

 

	 	OUTLOOK THERAPEUTICS, Inc.
	 	 
	 	 
	 	By:	/s/ Lawrence A. Kenyon
	 	 	Name: Lawrence A. Kenyon
	 	 	Title: Chief Financial Officer
	 	 
	 	 
	 	GMS VENTURE AND INVESTMENTS
	 	 
	 	 
	 	By:	/s/ Faisal Ghiath Munir Sukhtian
	 	 	Name: Faisal Ghiath Munir Sukhtian
	 	 	Title: Director

 

[Signature Page to Investor Rights Agreement]

 

    

     

    

 

Schedule I

 

Shareholder Representatives

 

		1.	Faisal
                                            G. Sukhtian (faisal@gmsholdings.com)

 

		2.	Yezan
                                            Haddadin (ymh@gmsholdings.com)SEPARATION AGREEMENT AND RELEASE

 

This Separation Agreement
(this “Agreement”), dated April 19, 2022 is entered into by and between Digirad Health, Inc. (the “Company”) and
Matthew G. Molchan (“Employee,” and, together with the Company, the “Parties”).

 

1.                 
The Parties acknowledge and agree that Employee’s last day of employment with the Company shall be May 2, 2022 (“Separation
Date”). Capitalized terms used without definition in this Agreement shall have the meanings set forth in the Employment Agreement
by and between Employee and Digirad Ultrascan Solutions, Inc., dated May 1, 2007 (the “Employment Agreement”) and the amendment
thereto between Employee and Digirad Corporation dated September 30, 2010 (the “Amendment”). Regardless of whether Employee
signs this Agreement:

 

(a)              
After the Separation Date, Employee will not hold any position with or on behalf of the Company, its parent corporation, subsidiaries,
divisions, affiliated entities, predecessors, successors and assigns. The Separation Date shall be the termination date of his employment
with the Company for all purposes, including for participation in and coverage under all benefit plans and programs sponsored by or through
the Company, except: (i) your existing coverage under any Company-sponsored medical or dental plans shall continue until the last day
of the month in which your Separation Date occurs; and (ii) following the Separation Date, you may elect to continue your medical coverage
pursuant to the Consolidated Omnibus Budget Reconciliation Act (“COBRA”). You will receive additional information concerning
your eligibility for COBRA continuation coverage in the mail from the Company’s COBRA Administrator.

 

(b)              
Employee shall receive his final paycheck, less applicable payroll deductions and all required withholdings on May 20, 2022, which
shall include: (i) any unpaid Base Salary and vacation accrued through the Separation Date and (ii) reimbursement for any unreimbursed
business expenses properly incurred through the Separation Date in accordance with and subject to the Company’s expense reimbursement
policies. For purposes of this agreement Base Salary is updated and defined as the Employee’s current salary.

 

2.                 
In consideration of Employee executing this Agreement within the twenty-one-day period immediately following receipt of
this Agreement (and not revoking acceptance prior to the Release Effective Date, defined below) and Employee’s compliance with this
Agreement the Company agrees to pay to Employee: (i) an amount equal to twelve months of Employee’s current Base Salary at the time
of the Separation Date, less applicable withholdings and deductions, in twenty-six equal bi-weekly installments following the Company’s
standard payroll schedule beginning with the Company’s first scheduled payroll period following Employee’s final paycheck
and Employee’s acceptance and non-revocation of this Agreement in accordance with Section 4, and (ii) reimbursement for Employee’s
actual cost of COBRA payments for a period of twelve months after substantiation with itemized receipts. Employee’s current Base
Salary is updated and defined as his current base salary of $415,000.00 per year or $15,961.54 per installment.

 

    1 

     

    

 

3.                 
Employee agrees and acknowledges that the payments described in Section 1(b) are the final compensation to which he is entitled
and he is not owed any other money or compensation for work performed. Employee agrees that the amounts described in Section 2 are the
full consideration for this Agreement and that those amounts exceed those severance benefits described in Section 3 of the Employment
Agreement and the Amendment and exceeds any benefits, compensation, or other financial consideration to which Employee would be entitled
absent his signing of this Agreement.

 

4.                 
Employee shall have up to twenty-one (21) days from the date of his receipt of this Agreement to consider the terms and
conditions of this Agreement. Employee may accept this Agreement at any time within the twenty-one (21) day period by executing it and
returning it to Rick Coleman, by email .pdf no later than 5:00 p.m. on the twenty-first (21st) day after Employee’s receipt
of this Agreement. Thereafter, Employee will have seven (7) days to revoke this Agreement by stating his desire to do so in writing to
Rick Coleman no later than 5:00 p.m. on the seventh (7th) day following the date Employee signs this Agreement. The effective
date of this Agreement shall be the eighth (8th) day following Employee’s signing of this Agreement (the “Release
Effective Date”), provided the Employee does not revoke the Agreement during the revocation period. In the event Employee does not
accept this Agreement as set forth above, or in the event Employee revokes this Agreement during the revocation period, this Agreement,
including but not limited to the obligation of the Company and its subsidiaries and affiliates to provide the payments referred to in
Section 2 above, shall automatically be deemed null and void.

 

5.                 
(a)In consideration of the payments and benefits referred to in Section 2 above, Employee for himself and for his heirs,
executors, and assigns (hereinafter collectively referred to as the “Releasors”), forever releases and discharges the Company
and any and all of its parent corporations, subsidiaries, divisions, affiliated entities, predecessors, successors and assigns, and any
and all of its and their employee benefit and/or pension plans and funds, and any and all of its and their past or present officers, directors,
stockholders, partners, managers, members, agents, trustees, administrators, employees and assigns (whether acting as agents for such
entities or in their individual capacities) (hereinafter collectively referred to as the “Releasees”), from any and all claims,
demands, causes of action, fees and liabilities of any kind whatsoever (based upon any legal or equitable theory, whether contractual,
common-law, statutory, decisional, federal, state, local or otherwise), whether known or unknown, which Releasors ever had, now have or
may have against the Releasees or any of them by reason of any actual or alleged act, omission, transaction, practice, conduct, occurrence,
or other matter from the beginning of the world to the Separation Date.

 

(b)              
Without limiting the generality of the foregoing subsection (a), this Agreement is intended to and shall release the Releasees
from any and all claims arising out of Employee’s employment with Releasees and/or the termination of Employee’s employment,
including but not limited to: (i) any claims of discrimination or harassment in employment on the basis of age, religion, gender, sexual
orientation, race, national origin, disability or any other legally protected characteristic, and of retaliation, under, without limitation,
Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 1981, the Americans with Disabilities Act, the Age Discrimination in Employment
Act, the Equal Pay Act, and all other federal, state and local equal employment opportunity and fair employment practice laws (all as
amended); (ii) any claims under the Employee Retirement Income Security Act of 1974 (except as set forth below), the Family and Medical
Leave Act and state and local laws of similar effect, the National Labor Relations Act, Workers Adjustment and Retraining Notification
Act, and other state and local laws of similar effect (all as amended); and (iii) any other claim (whether based on federal, state, or
local law, statutory or decisional) relating to or arising out of Employee’s employment or related to Employee’s Employment
Agreement or the Amendment, the terms and conditions of such employment, and/or the termination or separation of such employment, and/or
any of the events and decisions relating directly or indirectly to or surrounding the termination of that employment, including but not
limited to claims for breach of contract (express or implied), wrongful discharge, detrimental reliance, defamation, whistleblowing, harassment,
retaliation, mental distress, emotional distress, physical injury, humiliation or compensatory or punitive damages.

 

    2 

     

    

 

(c)              
Notwithstanding the foregoing, nothing in this Agreement shall be construed to prevent Employee from filing a charge with or participating
in an investigation conducted by any governmental agency, including, without limitation, the United States Equal Employment Opportunity
Commission (“EEOC”) or applicable state or city fair employment practices agency or the Securities and Exchange Commission
(“SEC”), to the extent required or permitted by law. Nevertheless, Employee understands and agrees that he is waiving any
relief available (including, for example, monetary damages or reinstatement), under any of the claims and/or causes of action waived in
Sections 5(a) and (b), including but not limited to financial benefit or monetary recovery from any lawsuit filed or settlement reached
by the EEOC with respect to any claims released and waived in this Agreement.

 

6.                 
(a)Employee agrees that he is not aware of any unlawful conduct related to his employment or engaged in by the Company
or any of the Releasees and has not and will not engage in any conduct that is injurious to the Company’s or any of the Releasees’
reputation or interest, including but not limited to disparaging (or inducing or encouraging others to disparage) the Company or the Releasees.
The Company and its affiliated entities agree that they will not disparage (or induce or encourage others to disparage) Employee. For
purposes of preceding sentence only, the Company shall mean executive officers or directors of the Company and its affiliated entities.

 

(b)              
It is acknowledged by virtue of Employee’s executive employment, Employee has information, including
but not limited to Confidential Information, that is or may be material to and necessary for the Company and Releasees to appropriately
and successfully conclude matters that involve third parties. As a result, following termination of employment, Employee agrees to assist,
and cooperate fully with, the Company and Releasees and to do so voluntarily (without legal compulsion) when such matters arise. This duty
of cooperation is intended to allow the Company and Releasees to meet their respective
legal obligations and satisfactorily conclude matters in a manner that achieves the best result possible for the Company and its affiliates.

 

    3 

     

    

 

(c)              
Employee shall provide, if requested by Rick Coleman or Marty Shirley, reasonable transition assistance during the three months
following the Termination Date. In the event that any request for assistance exceeds six hours in a week in the first month following
the Separation Date or three hours in a week in the following two months, the Company shall reimburse Employee for his time at the rate
of $200 per hour. With reasonable advance notice by Company, Employee agrees to travel for business purposes on behalf of Company up to
three times in the 90-day period following the Separation date. If requested to travel, pre-approved travel expenses will be reimbursed
according to the current Digirad Executive Management travel policies.  Employee will not be reimbursed for travel time. Notwithstanding
the above, Employee agrees to provide support to resolve ongoing litigation and tax matters for a period of one year following the Separation
Date.  If such support is required in the fourth through twelfth months following the Separation Date, the Company shall
provide reasonable notice subject to Employee’s availability, and shall reimburse Employee for his time at the rate of $200
per hour.

 

(d)              
Employee acknowledges that he will promptly return to the Company and its affiliates any and all originals and copies of documents,
materials, records, credit cards, keys, building passes, computers, cell phones, PDA’s and other electronic devices or other items
in his possession or control belonging to the Company or its affiliated entities or containing proprietary information relating to the
Company or its Affiliated Entities. Employee shall be permitted to retain all documents pertaining to his compensation and benefits. Employee
acknowledges that he may not disclose or discuss any confidential or Company (including affiliates) information.

 

Employee further agrees and acknowledges
that the two-year restrictions on non-competition and non-solicitation contained in Section 4 of the Employment Agreement, as modified
by the Amendment, shall continue on their terms, except as modified herein. Employee agrees that, for purposes of Section 4 of the Employment
Agreement and Amendment, the definition of Employer shall be modified to include the Company and its affiliated entities.  Employee
further agrees (i) not to solicit, sponsor, or recommend any current Digirad employee for work in any capacity, including as a partner,
consultant, contractor, or take any action which might cause or support the departure of any current Digirad employee from their current
employment with Digirad for a period of two years following the Separation Date, and (ii) to promptly notify Company of the employer
name and nature of responsibilities for any new position Employee secures during the two-year period following the Separation Date. Notwithstanding
the above, and anything contained in Section 4 or any other Section of the Employment Agreement, as modified by the Amendment, nothing
herein shall prevent Employee from working in the healthcare industry, including with a company engaged in Nuclear Imaging or Ultrasound
Imaging services, as long as Employee’s responsibilities are not related to the provision of such services.

 

7.                 
The terms and conditions of this Agreement are and shall be deemed to be confidential and shall not be disclosed by Employee
to any person or entity without the prior written consent of Rick Coleman or his successor, except if required by law, and to Employee’s
spouse/immediate family members, accountants or tax preparers, attorneys, and licensed financial advisors provided that they agree to
maintain the confidentiality of this Agreement. Employee further represents that he has not disclosed the terms and conditions of this
Agreement to anyone other than to the aforementioned persons.

 

8.                 
The making of this Agreement is not intended, and shall not be construed, as an admission that the Releasees have violated
any federal, state or local law (statutory or decisional), ordinance or regulation, breached any contract, or committed any wrong whatsoever
against Employee. The parties agree that this Agreement may not be used as evidence in a subsequent proceeding except in a proceeding
to enforce the terms of this Agreement.

 

    4 

     

    

 

9.                 
Employee acknowledges that: (a) he has carefully read this Agreement in its entirety; (b) he has been given an opportunity
to fully consider its terms for at least twenty-one (21) days; (c) he has been advised by the Company in writing to consult with
an attorney of his choosing in connection with this Agreement; (d) he fully understands the significance of all of the terms and conditions
of this Agreement and he has discussed it with his independent legal counsel, or has had a reasonable opportunity to do so; (e) he has
had answered to his satisfaction any questions he has asked with regard to the meaning and significance of any of the provisions of this
Agreement; and (f) he is signing this Agreement voluntarily and of his own free will and assents to all the terms and conditions contained
herein.

 

10.             
This Agreement is binding upon, and shall inure to the benefit of, the parties and their respective heirs, executors, administrators,
successors and assigns.

 

11.             
If any provision of this Agreement shall be held by a court of competent jurisdiction to be illegal, void, or unenforceable,
such provision shall be of no force and effect. However, the illegality or unenforceability of such provision shall have no effect upon,
and shall not impair the enforceability of, any other provision of this Agreement; provided, however, that, upon any finding by a court
of competent jurisdiction that any of the release or covenants provided for by Section 5, 6, and/or 7 above is illegal, void, or unenforceable,
Employee agrees to execute a release, waiver and/or covenant with substantially similar provisions that is legal and enforceable. Any
breach of Sections 5, 6, and/or 7 above by Employee or any post-employment covenants contained in the Employment Agreement or the Amendment
shall constitute a material breach of this Agreement as to which the Company may seek appropriate relief and shall entitle Company to
cease continuing payments or reimbursement under Section 2. Company shall notify Employee of a breach and, if such breach is capable of
cure in the Company’s discretion, provide Employee with an opportunity to cure of not less than 10 days prior to seeking any relief.

 

12.             
This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Georgia, without
regard to the conflict of laws provisions thereof. Actions to enforce the terms of this Agreement, or that relate to Employee’s
employment with the Company shall be submitted to the exclusive jurisdiction of any state or federal court sitting in Atlanta, Georgia.

 

13.             
This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together
shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the
parties and delivered to the other party. Facsimile or .pdf signatures shall have the same force and effect as original signatures.

 

14.             
This Agreement constitutes the complete understanding between the parties with respect to the termination of Employee’s
employment and service to the Company and its affiliates, and supersedes any and all agreements, understandings, and discussions, whether
written or oral, between the parties, except for the Employee Proprietary Information and Inventions Assignment Agreement, and the post-employment
covenants and obligations contained in the Employment Agreement or the Amendment, which remain in full effect. No amendment of any provision
of this Agreement shall be valid unless the same shall be in writing and signed by each of the parties hereto.

 

    5 

     

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Agreement this 19th day of April 2022.

 

	MATTHEW G. MOLCHAN	 	DIGIRAD HEALTH, INC.
	 	 	 
	/s/
Matthew G. Molchan	 	/s/ Richard K. Coleman, Jr.
	Signature of Employee	 	Signature of Authorized Representative
	 	 	Richard K. Coleman, Jr.
	 	 	 
	April 19, 2022	 	April 19, 2022
	Date	 	Date

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]